Purdue University

Purdue e-Pubs
Open Access Dissertations

Theses and Dissertations

Spring 2015

The pathological role of acrolein in experimental
autoimmune encephalomyelitis and multiple
sclerosis
Melissa A. Tully
Purdue University

Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations
Part of the Biomedical Engineering and Bioengineering Commons, Medicine and Health
Sciences Commons, Neuroscience and Neurobiology Commons, and the Nutritional Epidemiology
Commons
Recommended Citation
Tully, Melissa A., "The pathological role of acrolein in experimental autoimmune encephalomyelitis and multiple sclerosis" (2015).
Open Access Dissertations. 573.
https://docs.lib.purdue.edu/open_access_dissertations/573

This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact epubs@purdue.edu for
additional information.

*UDGXDWH6FKRRO)RUP30
5HYLVHG 0814 

PURDUE UNIVERSITY
GRADUATE SCHOOL
Thesis/Dissertation Acceptance
7KLVLVWRFHUWLI\WKDWWKHWKHVLVGLVVHUWDWLRQSUHSDUHG
%\ Melissa A. Tully
(QWLWOHG

THE PATHOLOGICAL ROLE OF ACROLEIN IN EXPERIMENTAL AUTOIMMUNE
ENCEPHALOMYELITIS AND MULITPLE SCLEROSIS

)RUWKHGHJUHHRI

Doctor of Philosophy

,VDSSURYHGE\WKHILQDOH[DPLQLQJFRPPLWWHH
RiyiShi
Kevin Hannon

Eric Nauman

Kevin Otto
To the best of my knowledge and as understood by the student in the Thesis/Dissertation Agreement,
Publication Delay, and Certification/Disclaimer (Graduate School Form 32), this thesis/dissertation
adheres to the provisions of Purdue University’s “Policy on Integrity in Research” and the use of
 copyrighted material.
Riyi Shi

$SSURYHGE\0DMRU3URIHVVRU V BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
$SSURYHGE\ George Wodicka
+HDGRIWKHDepartment *UDGXDWH3URJUDP

04/20/2015
'DWH

THE PATHOLOGICAL ROLE OF ACROLEIN IN EXPERIMENTAL
AUTOIMMUNE ENCEPHALOMYELITIS AND MULTIPLE SCLEROSIS

A Dissertation
Submitted to the Faculty
of
Purdue University
by
Melissa A. Tully

In Partial Fulfillment of the
Requirements for the Degree
of
Doctor of Philosophy

May 2015
Purdue University
West Lafayette, Indiana

ii

To my family, for their endless love and support

iii

ACKNOWLEDGEMENTS

I was extremely fortunate throughout the duration of this challenging journey
to have the unwavering support of my family, friends, colleagues and faculty
advisors. My deepest gratitude goes to everyone who worked hard to make my
graduate career at Purdue a success.
First and foremost, I would like to thank my faculty advisor Dr. Riyi Shi for
his mentorship and encouragement over the past four years. His infectious attitude
and genuine passion for science fueled my drive to continue on my quest for
discovery and made pursuing a Ph.D. an enjoyable experience. It has been my
sincere pleasure to have had the opportunity to learn and receive training in his
laboratory. Next, I would like to thank the members of my graduate committee, Dr.
Kevin Hannon, Dr. Eric Nauman and Dr. Kevin Otto, for their praises and criticisms,
equally, as they have both encouraged and challenged me to become a better
scientist. Thank you to my faculty collaborators Dr. Bruce Cooper and Dr. David
Mattson for their expertise. Also, thank you to the directors of the Indiana University
School of Medicine MSTP program, Dr. Maureen Harrington and Dr. Raghu
Mirmira, for their continuous encouragement. Special thanks to Sandy May and
Jan Receveur for your patience and helping me with administrative issues because
if you know me at all, you know I have had many.

iv
My time here at Purdue has been greatly enhanced by having the
opportunity to work with some very intelligent and wonderful people. I would like to
thank Dr. Gary Leung and Dr. Wenjing Sun for initiating the EAE study and
patiently teaching me all of the lab skills that I needed to independently conduct
the study upon their graduation; Dr. Sean Connell- for helping me whenever I
needed to engineer and construct something on a budget; Dr. Jonghyuck Park, Dr.
Désirée Schenck, Dr. Lingxing Zheng, Glen Acosta, Nick Race and Ran Tian- for
their collaborative efforts and willingness to help with troubleshooting when I
experienced difficulties.
Finally and most importantly, I would like to thank my family. I am extremely
fortunate to have a strong support system. Thank you to my parents for always
being there, no matter what, to my sister for always telling me the truth and keeping
me grounded and to my brother for making me laugh when things got a little too
serious. Words cannot even begin to express the how grateful I am for you guys.

v

TABLE OF CONTENTS

Page
LIST OF TABLES ............................................................................................... viii
LIST OF FIGURES ............................................................................................... ix
LIST OF ABBREVIATIONS .................................................................................. xi
ABSTRACT ........................................................................................................ xiii
CHAPTER 1. INTRODUCTION ........................................................................ 1
1.1
Clinical Features of Multiple Sclerosis ........................................... 1
1.2
Multiple Sclerosis Subtypes and Diagnostic Criteria ...................... 3
1.3
Pathogenesis of Multiple Sclerosis ................................................ 5
1.4
Oxidative Stress-Induced Damage to Axolemma and Myelin ........ 7
1.5
The Neurotoxic Nature of Acrolein ................................................. 7
1.5.1
Acrolein-Mediated Demyelination .................................................. 9
1.5.2
Acrolein-Induced Axonal Injury in Multiple Sclerosis ................... 10
1.5.3
Impairment of Mitochondrial Processes by Acrolein ................... 11
CHAPTER 2. NEUROPROTECTIVE ROLE OF ACROLEIN SCAVENGERS IN
EAE
................................................................................................. 13
2.1
Introduction .................................................................................. 13
2.2
Acrolein-Lysine Adducts Increased in EAE Spinal Cord Tissue .. 15
2.3
Hydralazine Attenuated Behavioral Deficit and Myelin Damage in
EAE Mice .................................................................................................... 16
2.4
Application of Hydralazine at Time of Symptom Emergence ....... 20
2.5
Summary and Significance .......................................................... 21
CHAPTER 3. ALLEVIATION OF BEHAVIORAL DEFICITS IN EAE USING
ALTERNATIVE ACROLEIN SCAVENGERS ...................................................... 22
3.1
Introduction .................................................................................. 22
3.2
Materials and methods ................................................................ 22
3.2.1
EAE mice............................................................................... 22
3.2.2
Behavioral Assessment ......................................................... 23
3.2.3
In vivo Phenelzine treatment ................................................. 23
3.2.4
In vivo EGCG treatment ........................................................ 23
3.2.5
Spinal Cord Tissue Preparation............................................. 24
3.3
Phenelzine ................................................................................... 24
3.4
Epigallocatchin gallate ................................................................. 27
3.5
Discussion ................................................................................... 29
CHAPTER 4. APPLICATION OF PEG AS A MEMBRANE REPAIR
AGENT
................................................................................................. 30

vi
Page
4.1
Introduction .................................................................................. 30
4.2
Materials and methods ................................................................ 32
4.2.1
EAE Mice............................................................................... 32
4.2.2
Horseradish Peroxidase Exclusion Test ................................ 32
4.2.3
PEG treatment and Preparation ............................................ 33
4.3
Results......................................................................................... 33
4.3.1
Axonal Membrane Damage and Its Alleviation by PEG ........ 33
4.3.2
PEG Treatment Significantly Reduced Symptom Severity and
Delayed Disease Onset in EAE Mice .......................................................... 35
4.4
Discussion ................................................................................... 37
CHAPTER 5. ESTABLISHMENT OF ACROLEIN DETECTION METHODS .. 40
5.1
Introduction .................................................................................. 40
5.1.1
GC and LC/MS-based techniques ............................................... 40
5.1.2
Antibody Detection of Acrolein-Protein Adducts .......................... 41
5.1.3
3-HPMA Detection Using LC/MS/MS .......................................... 42
5.1.4
Translational Nature of Acrolein Research .................................. 43
5.2
Materials and methods ................................................................ 43
5.2.1
Animal Preparation ................................................................ 43
5.2.2
EAE Model Induction and Behavioral Assessment ................ 44
5.2.3
Dot Immunoblotting ............................................................... 44
5.2.4
Animal Urine Collection ......................................................... 45
5.2.5
Subject Enrollment ................................................................ 45
5.2.6
Clinical Urine Collection......................................................... 45
5.2.7
Clinical Serum Collection....................................................... 46
5.2.8
3-HPMA Quantification Using LC/MS/MS.............................. 46
5.3
Results......................................................................................... 48
5.3.1
CNS and Systemic Elevation of Acrolein in EAE Mice .......... 48
5.3.2
Multiple Sclerosis Patients Exhibited Increased 3-HPMA in
Urine and Serum ......................................................................................... 51
5.4
Concluding Summary .................................................................. 56
CHAPTER 6. RESPIRATORY EXPOSURE TO ACROLEIN.......................... 59
6.1
Introduction .................................................................................. 59
6.1.1
Cigarette Smoking in Humans ..................................................... 60
6.1.2
Acrolein Inhalation in Mice ........................................................... 61
6.2
Materials and methods ................................................................ 62
6.2.1
Respiratory Exposure to Exogenous Acrolein ............................. 62
6.2.2
GC/MS ......................................................................................... 63
6.2.3
Detection of Acrolein-Lysine Adducts .......................................... 63
6.2.4
3-HPMA Quantification ................................................................ 63
6.2.5
Subject Recruitment .................................................................... 63
6.2.6
Clinical Urine Collection ............................................................... 64
6.3
Results......................................................................................... 64
6.3.1
Urine 3-HPMA Increased Following Acrolein Inhalation .............. 64

vii
Page
6.3.2
Respiratory Acrolein Exposure Increases Acrolein-Lysine Adducts
in Mouse Spinal Cord Tissue .......................................................................... 64
6.3.3
Systemic 3-HPMA Elevation in MS Patients Who are SelfReported Cigarette Smokers .......................................................................... 67
6.4
Discussion ................................................................................... 69
CHAPTER 7. ACROLEIN ELEVATION IN BOTH RR MS PATIENTS AND RR
EAE AND SYMPTOM ALLEVIATION IN RR EAE BY HYDRALAZINE .............. 72
7.1
Introduction .................................................................................. 72
7.2
Materials and methods ................................................................ 72
7.2.1
Subject Recruitment .............................................................. 72
7.2.2
Clinical Urine collection ......................................................... 72
7.2.3
Clinical Serum Collection....................................................... 73
7.2.4
RR EAE Induction and Behavioral Assessment .................... 73
7.2.5
Hydralazine Preparation and Application............................... 73
7.2.6
Animal Urine Collection ......................................................... 74
7.2.7
3-HPMA Analysis .................................................................. 74
7.2.8
Dot Immunoblotting ............................................................... 74
7.3
Premininary Results .................................................................... 74
7.3.1
Clinical 3-HPMA Elevations in Urine and Serum of RR MS
Patients
.............................................................................................. 74
7.3.2
Daily Hydralazine Application Ameliorated Motor Deficit in RR
EAE
.............................................................................................. 74
7.4
Discussion of Preliminary Findings .............................................. 77
CHAPTER 8. FURUTE DIRECTIONS ............................................................ 79
8.1
Examine the Effects of Exogenous Acrolein Exposure on
Development of the EAE Model...................................................................... 80
8.2
Employment of Minimally Invasive Neuroimaging Techniques with
3-HPMA Quantification to Determine How Endogenous Acrolein Concentration
Corresponds with CNS Structural Damage .................................................... 80
REFERENCES ................................................................................................... 81
VITA ................................................................................................................... 91

viii

LIST OF TABLES

Table

Page

Table 1.1 Clinical Signs and Symptoms of Multiple Sclerosis............................... 2
Table 1.2 Defintions of McDonald Criteria Terms ................................................. 4
Table 1.3 McDonald Criteria for diagnosis of multiple sclerosis............................ 5

ix

LIST OF FIGURES
Figure

Page

Figure 2.1 Induction of EAE Model ..................................................................... 14
Figure 2.2 Acrolein Scavenging by Hydralazine ................................................. 15
Figure 2.3 Dot Immunoblotting Quantification of Acrolein-Lysine Adducts in
Spinal Cord ......................................................................................................... 16
Figure 2.4 Hydralazine Therapy Ameliorated Motor Deficits. ............................. 18
Figure 2.5 Attenuation of Acrolein-Lysine Adducts by Hydralazine Treatment ... 19
Figure 2.6 Hydralazine Application at Symptom Onset. ..................................... 20
Figure 3.1 Acrolein Scavenging by Phenelzine ................................................. 26
Figure 3.2 Behavioral Assessment of Sham-Treated and Phenelzine-Treated
EAE Mice. ........................................................................................................... 27
Figure 3.3 Phenelzine Attenuated Behavioral Deficit in EAE .............................. 27
Figure 3.4 Phenelzine delayed Symptomatic Onset in EAE Mice....................... 28
Figure 3.5 Behavioral assessment of sham-treated and EGCG-treated EAE
mice .................................................................................................................... 29
Figure 4.1. Axonal Membrane Damage in EAE and its Alleviation by PEG. ....... 35
Figure 4.2 Evaluation of PEG as a Therapy for EAE Axonal Damage................ 37
Figure 4.3. PEG Delayed Symptom Onset in EAE Mice. .................................... 38
Figure 5.1 Behavioral Deficits Following MOG EAE Induction............................ 50
Figure 5.2. Determination of Acrolein Concentration Through Urine 3-HPMA
Measurement in EAE Mice. ................................................................................ 51
Figure 5.3. Elevations of CNS Acrolein Concentrations in EAE Mice ................. 52
Figure 5.4. Determination of Acrolein Concentration Through Urine 3-HPMA
Measurement in MS Patients and Healthy Individuals ........................................ 54
Figure 5.5. Determination of Acrolein Concentration Through Serum 3-HPMA
Measurements in MS Patients and Healthy Individuals ...................................... 55
Figure 5.6. Correlation of 3-HPMA Levels in Urine and Serum in MS Patients. . 56
Figure 6.1. Preclinical Assessment of the Effects of Respiratory Acrolein Exposure
in Mice. ............................................................................................................... 66

x
Figure

Page

Figure 6.2. Smoking in MS Patients is Associated with Higher Urine 3-HPMA... 68
Figure 6.3. Smoking Cigarettes is Associated with Higher EDSS Scores in Multiple
Sclerosis Patients. .............................................................................................. 68
Figure 7.1. Quantification of 3-HPMA in the Urine and Serum of RR MS
Patients. ............................................................................................................. 76
Figure 7.2. Hydralazine Application in RR EAE Augments Motor Function ........ 77

xi

LIST OF ABBREVIATIONS

3-HPMA

3-Hydroxypropyl Mercapturic Acid

ATP

Adenosine Triphosphate

BSA

Bovine Serum Albumin

CDC

Center for Disease Control

CNS

Central Nervous System

EAE

Experimental Autoimmune Encephalomyelitis

EGCG

Epigallocatechin gallate

EI

Electron Impact

FDA

Food and Drug Administration

GC

Gas Chromatography

GSH

Glutathione

HRP

Horseradish Peroxidase

LC/MS

Liquid Chromatography/Mass Spectrometry

LPO

Lipid Peroxidation

MAO-I

Monoamine Oxidase Inhibitor

MOG

Myelin Oligodendrocyte Glycoprotein

MS

Multiple Sclerosis

OCT

Optimum Cutting Temperature

PBS

Phosphate Buffer Saline

xii
PEG

Polyethylene Glycol

PLP

Proteolipid Lipoprotein

PP

Primary Progressive

ROS

Reactive Oxygen Species

RR

Relapsing Remitting

SP

Secondary Progressive

VGK

Voltage-Gated Potassium

xiii

ABSTRACT

Tully, Melissa A. Ph.D., Purdue University, May 2015. The Pathological Role of
Acrolein in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
Major Professor: Riyi Shi.

Multiple sclerosis (MS) is an autoimmune demyelinating neuropathy that affects
nearly 2.5 million people worldwide. Despite substantial efforts, few treatments are
currently available largely due to limited knowledge of pathogenic mechanisms
underlying the disease. The immune-inflammatory nature of the pathology has
prompted investigation of the role of oxidative stress in disease development and
progression; however targeting reactive oxygen species for neutralization has had
marginal success therapeutically, suggesting that an alternate oxidative stressrelated target would prove beneficial. Recently, our lab has implicated acrolein, a
highly reactive aldehyde that is both a byproduct and catalyst of lipid peroxidation,
as a potential therapeutic target and biomarker for MS diagnosis and symptom
monitoring. We have shown that acrolein is elevated in clinical MS cases and
experimental autoimmune encephalomyelitis (EAE), a murine model of MS.
Furthermore, pharmacological sequestering of acrolein afforded a neuroprotective
effect by suppressing tissue acrolein level, slowing disease progression, and
decreasing symptom severity. Acrolein can also be produced exogenously as a
pollutant from combustion engine exhaust, industrial processing, burning of

xiv
tobacco and overheated cooking oil vapors. The pathogenic role of endogenous
acrolein in MS raises the possibility that environmental exposure to acrolein could
potentially increase MS risk or exacerbate MS symptoms. Using a respiratory
exposure model in combination with urinary detection of an acrolein metabolite and
immunoblotting assessment of tissue acrolein-lysine adducts, we have
ascertained that inhalation of acrolein can cause accumulation of acrolein in mice
systemically and locally within the CNS. Additionally clinical acrolein assessment
using urine and serum samples revealed that MS patients who self-reported as
smokers demonstrated higher systemic acrolein levels and demonstrated greater
motor deficit compared to MS patients that did not smoke. These observations
indicate that acrolein is likely contributing to the mechanisms underlying symptom
development in EAE and MS and may serve as a therapeutic target and biomarker
for diagnosis, guiding treatment regimens and monitoring relapses.

1

CHAPTER 1. INTRODUCTION

1.1

Clinical Features of Multiple Sclerosis

Multiple sclerosis (MS) is an immune-mediated demyelinating disorder of
the central nervous system (CNS) that affects 1 of 1,000 people in the United
States and approximately 2.5 million globally. Two of three MS patients is female
and on average exhibit an onset of symptoms five years earlier than their male
counterparts [1, 2]. Along with differing risk associated with gender, MS incidence
and prevalence also appear to be related to geography, most commonly
presenting in Caucasians living in the cooler climates of the Northern hemisphere.
With an average onset of 23.5 years, MS patients have a mean life expectancy of
50 years and often require assistance with daily activities 10 years following
diagnosis due to severe disability [2, 3]. Additionally, patients were 3 times more
likely to experience premature mortality than the unaffected population by 38 years
following symptom onset [4]. With an annual patient cost of care of 47,000 dollars
and as a disease that presents relatively early in life, MS poses a substantial
financial burden on patients, their families, and society [5]. Furthermore, MS
patients are at greater risk of presenting with concomitant autoimmune diseases
such as autoimmune thyroid disease, type I diabetes mellitus, and inflammatory
bowel disease, perpetuating financial stress associated with increased healthcare
cost [6-9].
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Due to a global assault of CNS white matter tracts, MS presents clinically
as a collection of neurological sequelae that can often be mistaken as unrelated
[10]. Table 1.1 outlines patient-reported symptoms and/or those observed upon
physical examination for which an MS diagnosis should be considered.

Table 1.1 Clinical signs and symptoms of multiple sclerosis; adapted from [11]
Symptoms
Sensory
Disturbances

Pain

Balance/ Gait
Disturbances,
Ataxia
Vertigo

Visual Deficits

Description
Intense itching,
numbness,
tingling, pins and
needles,
tightness,
coldness,
imparitment of
joint position
sense, swelling
Trigeminal
neuralgia,
Lhermitte’s sign,
dysesthesia,
back/visceral pain,
tonic spasms
Observed
deviation in
walking pattern,
limb
discoordination
Severe dizziness,
specifically a
movement
hallucination
Complete/parital
loss, optic neuritis,
internuclear
opthalmoplegia,
diplopia

% Affected
100

% Presenting
30.7

40.3

0.5

30-50

8.9

45

1.7

15-75

15.9

3
Bowel/Bladder
Dysfunction
Sexual
Dysfunction
1.2

Urgency,
incontinence,
constipation
Complete;
Impaired

--

1

50;20

--

Multiple Sclerosis Subtypes and Diagnostic Criteria

MS presentation can differ in average age of onset, time course, and rate
of symptom progression, which resulted in the establishment of two main subtypes:
relapsing remitting (RR) and primary progressive (PP) [12]. RR MS accounts for
approximately 85% of cases, tends to present in younger patients between 25 and
33 years old and is characterized by transient CNS attacks with either partial or
complete symptomatic resolution, occurring one to two times per year. However,
RR MS patients generally transition into a phase deemed secondary progressive
(SP) at 40-44 years old in which they exhibit attacks without recovery. Absence of
recovery following an attack and the resulting slow, steady deterioration of the
patient is believed to correspond to permanent neurological impairment attributed
to axonal degeneration and loss of neuroplasticity [13]. PP MS is responsible for
the other 15% of cases and presents in older patients averaging from 35 to 39
years old [14]. PP MS shares many characteristics with SP MS, except that it is
not preceded by RR MS; PP MS patients, even in early stages of the disease, do
not experience physical recovery following an attack.
The diagnostic criteria for MS are explicitly described in the McDonald
Criteria which was first created in 2001 and outlines combinations of physical
examination findings and laboratory testing to afford sufficient evidence to
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definitively diagnose MS [15]. Since its inception, the Criteria have been revised
twice, once in 2005 and again in 2010, to incorporate further knowledge gained
pertaining to the disease as well as to account for advances in technology [16-19].
These revisions preserved both sensitivity and specificity of the Criteria as a
diagnostic tool and also the classification of symptoms as either disseminated in
space or in time (Table 1.2) [20]. Complete demonstration of any of the
combinations of parameters outlined in the criteria justifies a definitive MS
diagnosis (Table 1.3). The diagnosis of “possible MS” can be made if an MS
diagnosis is suspected, but some pieces of the criteria are absent. If the
requirements of the criteria are not met, other disorders should be considered.

Table 1.2 Defintions of McDonald Criteria Terms; adapted from [20]

Dissemination in Space (DIS)

Dissemination in Time (DIT)

MRI shows: ≥ 1 T2 lesion in ≥ 2 of the
following areas:
 Periventricular
 Juxtacortical
 Infratentorial
 Spinal cord
A new T2 or Gd-enhancing lesion on
follow-up MRI
(not dependent on timing of first scan)
OR
Gd-enhancing lesion(s) and nonenhancing lesion(s) present at the
same time
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Table 1.3 McDonald Criteria for diagnosis of multiple sclerosis; adapted from [20]
Clinical Presentation
 ≥ 2 attacks
 Objective clinical evidence of ≥ 2
lesions
OR
Objective clinical evidence of 1 lesion
with evidence of prior attack
 ≥ 2 attacks
 Objective clinical evidence of 1
lesion

 1 attack
 Objective clinical evidence of ≥ 2
lesions
 1 attack
 Objective clinical evidence of 1
lesion
Suggestive of PP MS

1.3

Additional Data Required

None

DIS
OR
Await further clinical attack suggestive
of a different site in the CNS
DIT
OR
Await second clinical attack
DIS + DIT
OR
Await further clinical attack
 1 year of disease progression
 2 of the following:
a. DIS in brain: ≥ 1 T2 lesion in MS
regions
b. DIS in spinal cord: ≥ 2 T2 cord
lesions
c. Positive CSF
d. Isoelectric focusing evidence of
oligoclonal bands
AND/OR Elevated IgG index

Pathogenesis of Multiple Sclerosis

Although the exact mechanisms remain to be elucidated, the clinical
features of MS can be attributed to a triad of neural tissue injury processes:
inflammation, demyelination, and axonal degeneration [2, 13]. Auto-reactive
myelin-specific T-lymphocytes appear to be the main culprits eliciting
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demyelination. Activated by molecular mimicry, these lymphocytes initiate a
cascade of subsequent events such as blood-brain-barrier disruption, microglial
activation, excitotoxicity, plaque development, and ultimately neurodegeneration
and microglial scarring [13, 21-23]. Evidence of inflammation can be seen in
biopsied plaques, which contain lymphocytes and macrophages, and additionally
myelin reactive T-cells are observed in the blood and CSF of MS patients [24-26].
Microglia contribute to the inflammatory atmosphere, instigated by the T-cells, by
releasing proteolytic enzymes, cytokines, oxidative products, and free radicals
creating an environment that is toxic to oligodendrocytes and myelin [27, 28].
Inflammation elicits demyelination and axonal damage, the process likely
underlying permanent neurological impairment and conduction failure. Axonal
injury has been recently recognized as playing a critical role in the symptomatic
development in MS patients [29-32]. Ultimately, compromise of axons is believed
to lead to the neuronal degeneration, cerebral atrophy, and permanent loss of
function, all of which are characteristic of late stage MS.
Despite the inflammatory and autoimmune nature of the disease, traditional
anti-inflammatory therapies have so far demonstrated marginal effect in
lengthening time between relapses, alleviating symptoms long-term, and slowing
disease progression [13, 33]. Development of a novel treatment strategy
necessitates additional study of pathogenic mechanisms. Establishment of welldefined links between the observed inflammatory reactions, demyelination, and
axonal damage will enable identification of more suitable pharmacologic targets.
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1.4

Oxidative Stress-Induced Damage to Axolemma and Mylein

Many recent studies suggest that oxidative stress underlies damaging
pathological processes of CNS diseases and trauma [34-37]. In part, this can be
explained by the inherent vulnerability of the CNS to oxidative stress due to low
levels of intrinsic anti-oxidants (catalase and GSH-peroxidase), high composition
of polyunsaturated lipids (membrane and myelin), and high quantities of ROS
produced by essential neurochemical processes in healthy CNS cells, relative to
other organ systems [34-39]. Consequently, in disease states, the CNS is
especially susceptible to oxidative insult by reactive oxygen species (ROS) and
lipid peroxidation (LPO) byproducts. Until recently, studies have predominantly
attempted to reduce oxidative damage in the CNS by pharmacologically targeting
ROS to alleviate neurotoxic effects [38, 40-42]. However, this therapeutic approach
has yielded inconsistent results in achieving symptomatic improvement in animal
models of CNS disease and trauma, leading researchers to target LPO products
therapeutically.
1.5

The Neurotoxic Nature of Acrolein

Acrolein, an α,β-unsaturated aldehyde and LPO byproduct, appears to have
a crucial role in mediating and perpetuating oxidative stress. Acrolein, produced
endogenously by lipid peroxidation and exogenously by burning tobacco, frying in
oils and petrol, and combustion of wood and plastic, has been implicated in various
diseases such as ischemia, spinal cord injury, respiratory diseases, traumatic
injury, chronic pain and neurodegenerative diseases by perpetuating oxidative
stress [34, 41, 43-47]. Of LPO aldehydes, acrolein is the most abundant and
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reactive. In fact, it has been reported to exceed concentrations of other aldehydes,
such as 4-hydroxynonenal, by 40 times and is highly reactive with crucial cell
components including phospholipids, proteins, and DNA [48-50]. Additonally, the
half-life of acrolein is considerably greater compared to ROS (days as opposed to
fractions of a second) [48]. Furthermore, acrolein can act as a catalyst to produce
more acrolein and ROS intitiating a detrimental cycle of oxidative stress. Taken
together, evidence indicates that acrolein is capable of instigating and perpetuating
oxidative stress.
In addition to endogenous oxidative processes, exposure to acrolein can
also occur by way of an exogenous environmental pollutant such as emissions
from petrol combustion, cigarette smoking, manufacturing processes, and frying
food [51-55]. This raises the possibility of an additive effect when considering
acrolein exposure, potentially rendering individuals with pathologically high levels
of endogenous acrolein more susceptible to environmental acrolein, since
acrolein, regardless of its source, can exacerbate oxidative stress.
Due to its extended half-life compared to ROS, targeting endogenous
acrolein has promising applications in diagnosing, monitoring and treating MS.
Many current treatments of MS are geared towards preserving functional loss,
suppressing inflammation, and reducing immune response associated with the
disease such as 4-aminopyridine (Ampyra), Interferons, Glatiramer acetate
(Copaxone), Natalizumab (Tysabri), and Fingolimod (Gilenya). Unfortunately,
these drugs are very expensive, especially for uninsured patients. Some acrolein
scavenging drugs currently being examined, such as hydralazine, are substantially

9
less expensive, already FDA approved and have been shown to be effective at
both delaying onset and decreasing the severity of symptoms in in vitro and in vivo
studies [56].
1.5.1 Acrolein-Mediated Demyelination
Demyelination within the CNS, a main feature of MS development and
progression, manifests as a transient functional loss characteristic of RRMS [13,
33]. Loss of myelin structural integrity hinders neuron function by increasing the
energy needed for action potential propagation. If myelin is not repaired, adenosine
triphosphate (ATP) stores will eventually be depleted and action potential
conduction will cease. Acrolein is not only capable of directly damaging myelin but
also anchoring proteins that secure myelin to the axon. In the event of damage to
an anchoring protein, myelin will split and separate from the axon; a process known
as decompaction. In instances where myelin damage is severe and myelin
decompaction occurs, voltage-gated potassium (VGK) channels are no longer
localized to the juxtaparanodal region but instead aberrantly expressed along the
length of the axon. Abberant expression of VGK channels also leads to impairment
of action potential propagation due to the unregulated outward current of
potassium ions and loss of ionic gradient essential for action potential generation
[57-59]. In one ex vivo study, myelin retraction from the nodes of Ranvier and
myelin decompaction were observed following isolated spinal cord incubation in
acrolein [58]. Furthermore, exposure of juxtaparanodal VGK, absent action
potential propagation, and aberrant VGK expression were reported [58, 60].
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Previously thought to be separate aspects of the MS pathology,
demyelination and axolemma damage now appear to be more related than
previously thought; damage to axons and/or myelin can affect ionic gradients and
localization of channels along the axon, essential processes in signal conduction
[61-64]. Acrolein is capable of affecting both of these neuronal components and
therefore is likely a contributor to detrimental processes underlying function
deterioration in MS patients.
1.5.2 Acrolein-Induced Axonal Injury in Multiple Sclerosis
Clinical ex vivo studies assessing markers of myelin disruption and axonal
damage in MS patient brain tissue were the first to implicate the axonal
degeneration as an important mechanism underlying symptoms of MS. The
studies revealed a large quantity of transected axons, which could explain
permanent neurological impairment seen in late stages of MS [32, 65]. In another
study, inflammatory damage to axons led to conduction deficits and emergence of
symptoms in animal models and clinical MS cases [32, 66]. Evidence of the critical
role of axonal injury in MS, has prompted some to hypothesize that axonal injury
resulting in degeneration would elicit a permanent functional deficit like that seen
in SP- and PP MS [32, 65].
As stated previously, acrolein can directly injure axolemma, likely due to the
phospholipid component. Additionally, demyelination, aside from previously
mentioned detrimental effects, renders the axonal membrane vulnerable to the
harsh extracellular environment of inflammatory mediators, acrolein and other
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highly reactive molecules. In this way, acrolein is capable of inflicting membrane
damage both directly and indirectly.
We have shown acrolein exposure compromises the structural integrity of
cell membrane and prolonged exposure results in an increase in axon permeability
and a halt of compound action potential propagation [41, 67, 68]. Application of
acrolein scavenger, hydralazine, proved to be neuroprotective to axons in both in
vivo and in vitro spinal cord trauma models. Taken together, there is extensive
evidence implicating acrolein as an instigator of axonal damage and ultimately,
axonal degeneration [59].
1.5.3 Direct and Indirect Impairment of Mitochondrial Processes by Acrolein
Mitochondrial dysfunction is another mechanism believed to underlie
symptoms characteristic of MS compromising energy output and ultimately, if left
unchecked, initiating cell death pathways. Damage to myelin and axolemma
results in an inward calcium current, subsequently triggering cell death pathways
and release of mediators that can directly injure mitochondria [33]. In fact,
mitochondria may even be more susceptible to acrolein and ROS than other
cellular structures.
Mitochondria generate ATP to support cell survival, growth and function;
however the electron transport chain causes the non-pathological generation of
ROS. In this way, mitochondrial dysfunction not only affects the amount if ATP
supplied to the cell but also directly exacerbates oxidative stress through the
release of additional ROS. Thus, in a pathological state, mitochondria are
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inherently vulnerable to the inflammatory environment and upon death further
promote an oxidative stress and CNS damage [69, 70].
Mitochondrial dysfunction has been elicited by acrolein in cardiac tissue,
brain and spinal cord [71-73]. In one study, upon exposure to acrolein, isolated
mitochondria depleted glutathione (GSH) and increased ROS levels [71]. The
brain relies almost exclusively on GSH as an antioxidant due to intrinsically low
levels of catalase, further establishing acrolein as a potent neurotoxin [71].
Furthermore, acrolein is known to directly inhibit function of adenine nucleotide
translocase through the binding of cysteine residues, an essential component of
the electron transport chain. In this way acrolein is capable of directly injuring
mitochondria, halting cellular respiration and perpetuating oxidative stress [71, 74,
75].
.
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CHAPTER 2. NEUROPROTECTIVE ROLE OF ACROLEIN SCAVENGERS IN
EAE

2.1

Introduction

The therapeutic utility of scavenging acrolein in EAE was first studied in the
Shi laboratory. The study employed the FDA-approved antihypertensive
hydralazine, which had been previously demonstrated to effectively scavenge
acrolein in vitro at concentrations well below those currently approved for the
treatment of hypertension. EAE was induced in female C57BL/6 mice by the
subcutaneous injection of myelin oligodendrocyte/complete freunds adjuvant at
caudal and rostral ends of the mouse spinal cord to elicit an autoimmune response
to myelin (Figure 2.1). Deconjugated pertussis toxin was administered
intraperitoneally at the time of myelin oligodendrocyte glycoprotein (MOG)
application and again 24 hours later to increase blood brain barrier permeability
and facilitate immune cell infiltration into the CNS. Hydralazine (1mg/kg) was
administered I.P. daily to the treatment group beginning on day of model induction.
Behavioral scores were monitored through the conclusion of the study, at which
point animals were euthanized and immunoblotting and immunohistochemical
techniques were performed to quantify acrolein-lysine adduct level within the spinal
cord and myelin integrity, respectively. Acrolein was found at significantly greater
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levels in EAE spinal cords when compared to both control and hydralazine-treated
groups. Additionally, application of an acrolein scavenger in EAE mice provided a
neuroprotective effect, significantly attenuating behavioral deficit and reducing
demyelination relative to untreated EAE counterparts. These results demonstrate
the potential of acrolein scavenging as an effective therapeutic strategy in
combating the detrimental effects of the EAE model and potentially even in the
treatment of clinical cases of MS.

Figure 2.1 Induction of EAE model. C57BL/6 mice were injected subcutaneously
with MOG emulsion at rostral and caudal ends of the spinal column. An
intraperitoneal injection of deconjugated pertussis toxin was administered at time
of MOG injection and, again, 24-36 hours later.
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Figure 2.2 Acrolein Scavenging by Hydralazine. Schematic of mechanism by
which hydralazine neutralizes acrolein. Acrolein binds to hydrazine group of
hydralazine.
2.2

Acrolein-Lysine Adducts Increased in EAE Spinal Cord Tissue

Acrolein-lysine adduct level in the spinal cord was quantified using
immunoblotting in three groups: saline-treated control mice (n=3), EAE mice (n=3)
and hydralazine-treated EAE mice (n=3). Untreated EAE mice exhibited
significantly increased levels of acrolein-lysine adducts (20.27 ± 3.0 a.u.)
compared to saline treated control mice (12.30 ± 1.3 a.u., p<0.05, Fig 2.2 B).
Hydralazine-treated EAE mice (15.4 ± 1.6 a.u.) also demonstrated a decrease in
acrolein-lysine adduct level relative to control, although this difference was not
found to be significant.
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Figure 2.3 Dot Immunoblotting Quantification of Acrolein-Lysine Adducts in
Spinal Cord. Immunoblotting demonstrated an increase in acrolein-lysine adduct
level in EAE mouse spinal cord. Band intensities were quantified using ImageJ
and expressed in arbitrary units. (A) Representative blot for each group. (B)
Acrolein-lysine adduct level was significantly increased in untreated EAE mice
(20.27 ± 3.0 a.u.) relative to sham-treated control mice (12.30 ± 1.3 a.u., p<0.05).
Hydralazine-treated EAE mice exhibited an acrolein lysine adduct level of 15.14
± 1.6 a.u. Statistical analysis was performed using a one-way ANOVA and posthoc tests. All data are expressed as mean ± SEM.

2.3

Hydralazine Attenuated Behavioral Deficit and Myelin Damage in EAE
mice
Behavioral assessments of hydralazine-treated and saline-treated EAE

mice were preformed daily throughout the course of the study using a 5-point
behavioral scale (Figure 2.2 A). The average onset of symptoms in the
hydralazine-treated group (21.73 ± 2.1 days post-induction) was significantly
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prolonged compared to their saline-treated counterparts (15.42 ± 0.4 days postinduction, p<0.01, Figure 2.2 B). Additionally, symptom severity was quantified by
averaging the highest scores for individual animals within each group starting.
Hydralazine-treated EAE mice (1.72 ± 0.4) demonstrated significantly lower
behavioral scores than the saline-treated EAE mice (3.33 ± 0.3, p<0.05, Figure 2.2
C). For myelin quantification, thoracic spinal cord segments were extracted from
saline-treated EAE, hydralazine-treated EAE, and controls, sectioned and stained
with fluoromyelin. Control sections did not exhibit signs of demyelination. There
was a statistically significant difference in demyelination area between salinetreated (25.58 ± 3.8%, n=3) and hydralazine-treated (5.10 ± 4.2%, n=3, p<0.05)
EAE groups (Figure 2.3).
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Figure 2.4 Hydralazine Therapy Ameliorated Motor Deficits. (A) Behavioral
assessment of saline-treated EAE and hydralazine-treated EAE mice (p<0.01
when groups compared after day 17). (B) Hydralazine treatment delayed
symptomatic onset of EAE relative to saline-treated EAE (p<0.01). (C) Mean
peak behavioral score was averaged for each group. Hydralazine-treated EAE
mice exhibited a significantly lower peak behavioral score (p<0.05).
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Figure 2.5 Attenuation of Acrolein-Lysine Adducts by Hydralazine Treatment.
Immunohistochemical analysis of myelin, using a myelin basic protein (MBP)
stain. Quantification was carried out using ImageJ. Spinal cords from the salinetreated EAE group experienced significantly increased demyelination compared
to their hydralazine-treated counterparts (p<0.05).

20
2.4

Application of Hydralazine at Time of Symptom Emergence

Although acrolein scavenging using hydralazine was shown to be an
effective neuroprotective strategy in EAE, it is important to note that treatment with
hydralazine began at the time of model induction. However in a clinical scenario,
a patient would not be treated for a disorder until they present with obvious,
diagnosable symptoms. To address this fundamental issue and ascertain the
clinical utility of acrolein scavenging, we conducted a study in which mice were not
treated with hydralazine until behavioral deficit emerged (score of 1-tail paralysis).
Even with delayed application of hydralazine, a neuroprotective effect was still
observed, in which rate of symptom progression and behavioral scores were
significantly decreased in hydralazine-treated EAE mice relative to their salinetreated counterparts.

Figure 2.6 Hydralazine Application at Symptom Onset. (Left) Behavioral score of
saline-treated EAE mice and EAE mice when treated with hydralazine at
symptom onset. Treated mice displayed significantly lower EAE scores than the
sham treated group
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2.5

Summary and Significance

This study further demonstrated the neurotoxic nature of acrolein and
implicated it as a relevant pathologic factor in EAE and likely in MS as well.
Acrolein-lysine adducts were detected at significantly increased levels in EAE mice
in concordance with emergence of motor deficit. Furthermore, daily administration
acrolein scavenger hydralazine conferred a neuroprotective effect, attenuating,
reducing severity and delaying onset of motor deficit in EAE mice when applied at
time of model induction through the end of the study. Ex vivo analysis of myelin
using immunohistochemistry demonstrated that hydralazine treatment also
resulted in a significant reduction in demyelination within thoracic white matter.
Additionally, when hydralazine was administered when EAE animals first
presented with tail paralysis, the earliest sign of EAE motor impairment, significant
reduction in behavioral score was observed in the treatment group. In light of this
finding, it is reasonable to suggest the potential of acrolein scavenging for
treatment of clinical cases of MS. Treatment application at emergence of
symptoms is a more clinically relevant, due to treatment in clinical scenarios
beginning when patients present to their physician with a problematic symptoms.
Hydralazine is an effective scavenger for both acrolein and acrolein-protein
adducts and attenuated neurotoxic effects in the EAE model when applied at time
of model induction or at emergence of motor deficit. Since hydralazine is already
an FDA-approved compound and doses used in this study are safe in humans,
therapeutic acrolein scavenging could potentially be employed in the future as a
treatment for MS patients with relative ease.
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CHAPTER 3. ALLEVIATION OF BEHAVIORAL IN EAE USING ALTERNATIVE
ACROLEIN SCAVENGERS

3.1

Introduction

Due to the demonstrated neuroprotective effects of hydralazine treatment
in the EAE model, acrolein scavenging has proven to be an effective treatment to
improve motor function and delay symptom onset. In order to further establish the
therapeutic benefit of scavenging acrolein, it is crucial to demonstrate that the
acrolein scavenging capability of hydralazine underlies its therapeutic utility in the
EAE model, rather than its currently approved usage as an antihypertensive.

As

such, two alternative acrolein scavengers, phenelzine, an MAO-I antidepressant,
and EGCG, a green tea catechin, were identified as other compounds containing
hydrazine groups, the functional group of acrolein scavengers, and evaluated in
the same manner as hydralazine.
3.2

Materials and methods

3.2.1 Experimental Autoimmune Encephalomyelitis (EAE) mice
Female C57BL/6 mice were injected with 0.1 mL MOG/complete Freunds
adjuvant emulsion (MOG) (Hooke Laboraties, Lawrence, MA) subcutaneously
over the caudal and rostral ends of the spinal cord.

This mixture mimics

endogenous proteins and creates an immune response to myelin in the central
nervous system.

Immediately following the emulsion injection, 0.1 mL of
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deconjugated pertussis toxin, (Hooke Laboratories) which is believed to create a
more permeable blood brain barrier and hasten the onset of symptoms, was given
intraperitoneally and again 24 hours later.
3.2.2 Behavioral Assessment
Behavioral assessment was performed using a 5-point scale for
quantification. Animals were placed on a grate to observe walking ability and
motor function. The scale is as follows: 0 – no deficit; 1 – limp tail only; 2 – hind
limb paresis without frank leg dragging; 3 – partial hind limb weakness with one or
both legs dragging; 4 – complete hind limb paralysis; 5 – moribund, paralysis in
hind limbs and forelimbs. The animals were monitored three times for the first
week and then daily until the end of the study.
3.2.3 In vivo phenelzine treatment
Phenelzine sulfate salt (Sigma Aldrich) was dissolved in phosphate buffered
saline (1x) and then sterilized through a vacuum filter. Intraperitoneal phenelzine
treatment (15 mg/kg, 0.1 mL) was intiated at three different time points: day of
induction, at behavioral symptom onset (score=1), and at symptom peak
(score=3). Control animals received intraperitoneal injections of saline rather than
phenelzine.
3.2.4 In vivo EGCG treatment
PBS was bubbled with nitrogen for five minutes before epigallocatechin
gallate (Sigma Aldrich, St. Louis, MO) was dissolved at a concentration of 4
mg/mL. Following dissolution, the solution was bubbled further to prevent autooxidation. After bubbling, the solution was sterilized using a 0.2 um syringe filter
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under nitrogen. Daily treatments of EGCG (20 mg/kg) were administered I.P. at a
volume of 0.1 mL, starting on day of induction through the conclusion of study.
Control animals received 0.1 mL saline as a sham treatment.
3.2.5 Spinal cord tissue preparation
Animals were anesthetized with a Ketamine (90 mg/kg) and Xylazine (10
mg/kg) and then perfused with cold Krebs solution (124 mM NaCl, 2 mM KCl, 1.2
mM KH2PO4, 1.3 mM MgSO4, 2 mM CaCl2, 10 mM dextrose, 26 mM NaHCO3,
10 mM sodium ascorbate) to both lower the body temperature and drain the blood.
For immunoblotting, the spinal column was then quickly removed and a complete
laminectomy performed. The spinal cord was then excised from the vertebrae and
placed in cold oxygenated Krebs solution.
For immunohistochemical analyses, following perfusion with Krebs solution,
animals were subsequently perfused with 4% paraformaldehyde. The spinal
column was then removed and incubated in 4% PFA for 1 hr. The spinal cords
were then extracted from the spinal column and cut into three 2 cm sections:
cervical, thoracic and caudal. Spinal cord segments were then incubated in 15%
sucrose for 24 hrs and then in 30% sucrose for 24 hrs. Tissue was then embedded
and frozen in OCT compound until slicing.
3.3

Phenelzine

Phenelzine is an FDA-approved MAO-I antidepressant that has acrolein
scavenging capabilities. In order to further establish acrolein scavenging as a novel
therapeutic strategy in EAE and MS, it was critical to demonstrate that two
structurally distinct drugs apart from acrolein scavenging groups, were both able
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to lower acrolein levels within the spinal cord and provide a neuroprotective effect.
When administered on the day of model induction, in the same manner as in 2.4,
phenelzine treatment, like hydralazine, resulted in delayed onset of symptoms,
reduced symptom severity, and slowed disease progression (Fig 3.1). These
findings further support the pathologic role of acrolein in EAE and the potential of
scavenging acrolein as a novel therapeutic strategy to improve quality of life for
MS patients.

Figure 3.1 Acrolein Scavenging by Phenelzine. Schematic of mechanism by
which phenelzine neutralizes acrolein. Acrolein binds to hydrazine group of
phenelzine.
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Figure 3.2 Behavioral Assessment of Sham-Treated (n=8) and PhenelzineTreated EAE Mice (n=8). Phenelzine-treated mice demonstrated a delayed onset
of symptoms, decreased symptom severity, and slowed symptom progression
relative to sham-treated controls (p<0.1).

Figure 3.3 Phenelzine Attenuated Behavioral Deficit in EAE Mice. Treatment with
phenelzine significantly decreased mean behavioral score (1.3±0.7; n=6) relative
to control sham-saline treated mice (3.3±0.25; n=12; p<0.005).
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Figure 3.4 Phenelzine delayed Symptomatic Onset in EAE Mice. Phenelzinetreated animals exhibited a significantly delayed onset (23.5 ±7.2; n=6) when
compared to controls (15.4±2.9; n=12; p<0.001)
3.4

Epigallocatechin Gallate (EGCG)

EGCG is an antioxidant naturally present in green tea and has been shown
to have therapeutic utility in other diseases such as cancer, HIV, and other
neurodegenerative diseases. In fact, EGCG has already demonstrated potential
as a treatment for MS; however mechanisms through which it exerts its
neuroprotective effects have yet to be fully characterized. However, as an antioxidant and acrolein scavenger, EGCG holds great promise as an effective natural
compound to combat oxidative stress. In this regard, the current study aims to
evaluate the effectiveness of EGCG in alleviating oxidative stress, particularly its
ability to mitigate neurodegenerative processes by sequestering acrolein in vivo in
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a murine model of MS. Two groups of EAE mice, one sham-treated with 0.1mL
PBS and the other treated with 0.1mL of EGCG (20 mg/kg), were subjected to daily
behavioral assessment for 28 days. After which mice were euthanized and spinal
cords removed for morphological assessment. This study is ongoing, however
preliminary behavioral data is presented below. Preliminary results indicate that
EGCG has the potential to ease behavioral deficit in EAE mice (Fig 3.2).

Figure 3.5 Behavioral assessment of sham-treated and EGCG-treated EAE mice.
EGCG treatment demonstrates positive preliminary results as an acrolein
scavenger, particularly in decelerating disease progression.
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3.5

Discussion

In order to further establish acrolein scavenging as a therapeutic approach
for the treatment of MS, identification of alternative acrolein scavengers is
imperative. The two alternative scavengers identified above, phenelzine and
EGCG, performed similarly to hydralazine when applied to improve behavioral
outcomes in the EAE model. The commonality of these three compounds lies in
the fact that they each contain a hydrazine group(s), which is the component
responsible for the binding and neutralization of acrolein. As such, this evidence
indicates that the therapeutic benefit of hydralazine in the initial study can indeed
be attributed to its acrolein scavenging properties.

30

CHAPTER 4. APPLICATION OF POLYETHYLENE GLYCOL (PEG) AS A
MEMBRANE REPAIR AGENT

4.1

Introduction

It is widely accepted that inflammation is the primary component of the MS
pathology, however the exact mechanisms which instigate CNS damage remain
incompletely characterized [13, 33]]. Although demyelination is considered the
prominent pathologic feature underlying symptom development in MS patients,
recent studies indicate that axonal injury and subsequent degeneration also
contribute to loss of conduction [2, 76]. These observations indicate that injury to
either myelin or axon could potentially manifest as neurological deficits
characteristic of MS. Furthermore, axonal degeneration has been suggested as
the underlying cause for the transition from RR MS to SP MS due to the fact that
this type of damage is irreversible, preventing complete remission following a
relapse [77]. This theory is supported by marginal success of therapies directed
solely at myelin preservation, particularly in more advanced stages of the disease
[13].
In light of these findings, it is critical to further elucidate the role of axonal
damage in MS and to explore therapeutic strategies aimed at neuronal protection
or repair. Specifically, the cellular processes that are responsible for initiating
axonal degeneration remain insufficiently characterized.

Previously, our lab

demonstrated that traumatic insult to axonal membrane is capable of prompting
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axonal degeneration in a spinal cord injury model [78-80]. Interestingly, acrolein,
known to play a role in myelin degradation observed in EAE, is also capable of
reacting with lipid in the axonal membrane, eliciting damage, and disrupting the
structural integrity of the axolemma [41, 46, 68, 81]. As such, we postulate that
acrolein could be a pathological factor underlying axonal membrane damage,
ultimately leading to axon degeneration and functional loss in MS.
To rescue axons with damaged axolemma, PEG, a hydrophilic bioinert
polymer capable of sealing membrane and promoting cell survival, was
administered intraperitoneally [82-84]. In another study, PEG effectively restored
axolemmal integrity in an animal model of spinal cord injury [84-86]. Despite its
promise in treatment of traumatic CNS injuries, PEG has yet to be investigated as
a therapy in other disease in which axolemma damage is indicated, such as MS.
PEG has the potential to rescue damaged axons within the CNS and consequently
prevent neurodegeneration. In order to evaluate the therapeutic potential of PEG
in EAE, first it is crucial to establish that axon damage occurs in EAE and
corresponds with functional deficit. Once this is confirmed we will proceed to
evaluate the therapeutic benefit of PEG by evaluating motor function in EAE mice
and assessing membrane permeability following spinal cord extraction. If
successful, this study could provide a whole new avenue in the treatment of MS
and other diseases in which axonal injury and degeneration are implicated.
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4.2

Materials and methods

4.2.1 Experimental Autoimmune Encephalomyelitis Mice
See 3.2.1
4.2.2 Horseradish Peroxidase Exclusion Test
Mice were divided into 4 groups: healthy control mice, PEG-treated EAE
mice EAE mice prior to onset of symptoms, and EAE mice exhibiting peak
symptoms. Behavior was monitored daily as previously described and at the study
conclusion animals were anesthetized with Ketamine (90 mg/kg) and Xylazine (10
mg/kg) and perfused with oxygenated Kreb’s solution [56]. The spinal columns
were removed and the spinal cords were excised by performing a complete
laminectomy. The excised spinal cord was then incubated in a solution of cold,
oxygenated Krebs solution and 0.015% horseradish peroxidase (Sigma Type IV,
Sigma Aldrich) for two hours.

The spinal cords were then fixed at room

temperature in 2.5% glutaraldehyde and phosphate buffer for four hours. Postfixation, 30 µm sections of the tissue were cut using a Vibratome (Electron
Microscopy Science, Hatfield, PA, USA). Then the tissue was incubated in a
diaminobenzidene solution to visualize HRP uptake through injured axolemma.
Using a microscope and computer, images of the stained spinal cord sections were
acquired. With the use of ImageJ analysis stained axons were tallied and conveyed
as density (axons/mm2) [78, 79, 81, 86].
4.2.3 Polyethylene Glycol Treatment and Preparation
A 30% solution of polyethylene glycol (295906, Sigma Aldrich, St. Louis,
MO, USA) in phosphate buffered saline was made and subsequently filtered for

33
sterilization. A volume of 0.1 mL was administered intraperitoneally daily starting
from the day of model induction. Control animals received a sham saline injection
in lieu of PEG.

4.3

Results

4.3.1 Axonal Membrane Damage and Its Alleviation by PEG in EAE Mice
Using the HRP-exclusion assay, we first assessed the degree of axonal
membrane damage in the spinal cords of EAE mice: control mice, EAE mice before
symptom onset, EAE mice at peak bahvioral deficit, and PEG-treated EAE mice.
The average HRP labeling for these conditions was 867 ± 172 axons/mm2, 3337
± 719 axons/mm2, 6510 ± 957 axons/mm2 and 1602 ± 357 axons/mm2,
respectively (Fig 4.1).

Both pre-symptom and peak-symptom mice exhibited

significantly increased HRP uptake relative to healthy controls (P<0.05; P<0.05).
In order to ascertain whether PEG can effectively repair the injured axolemma,
EAE mice were treated daily with 0.1 mL 30% PEG and treatment was initiated on
day of model induction. Interestingly, we have determined that PEG treated
animals demonstrated significantly lower HRP uptake than the peak deficit EAE
group.
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Figure 4.1 Axonal Membrane Damage in EAE and its Alleviation by PEG.
Horseradish peroxidase (HRP)-exclusion test determined amount of axonal
membrane damage in healthy control mice (n=3), pre-symptom EAE mice (n=5),
peak symptom EAE mice (n=4), and PEG-treated mice (n=5). A-D) The images
represent HRP-stained sections of spinal cord tissue from the four groups. Solid
arrows denote areas in which HRP did not penetrate the cell while the open
arrows point to areas depicting HRP penetration revealing increased axonal
membrane permeability. E) The bar graph quantifies HRP uptake in each group.
The value for control group is 867±172 axons/mm2. The peak symptom group
had the highest levels of axonal damage (6510 ± 957 axons/mm2 , P < 0.05
compared to control) while the pre-symptom group exhibited increased levels
compared to the control group (3337 ± 719 axons/mm2, P < 0.05 compared to
control). The HRP labeling in the EAE/PEG-treated group (1602 ± 357
axons/mm2) is significantly lower than EAE group (p<0.05).
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4.3.2 PEG Treatment Significantly Reduced Symptom Severity and Delayed
Disease Onset in EAE mice
In order to ascertain the effectiveness of PEG treatment, behavioral scores
from two experimental groups EAE and PEG-treated EAE were compared.
Behavioral scores for each animal were recorded daily for 4 weeks as previously
described [56].

Figure 4.2 demonstrates the relationship between average

behavioral score over time for the two groups. The EAE mice that received PEG
treatment demonstrated significantly lower behavioral score when compared to
their untreated counterparts during days 16 to 25. The mean of the peak scores
for each animal were then calculated and PEG-treated EAE mice demonstrated
significantly lower mean peak score (1.91 ± 0.4) than the EAE mice (3.33 ± 0.3, P
< 0.005) (Fig 4.2 inset).
Furthermore, PEG application also delayed the onset of EAE symptoms
(Figure 4.3 inset). Sham treated EAE mice, experienced symptomatic onset as
expected, between days 13 and 18, while the PEG-treated EAE mice tended to
develop initial symptoms at a later time point, as indicated by a delayed mean time
of symptom onset. Specifically, five PEG-treated animals developed between days
13 and 18 (similar to sham treated group), three experienced an onset between
days 20 and 26, and three mice did not develop symptoms during the entire four
week observation period (for averaging purposes day of onset for these animals
was recorded as day 28). The mean day of symptomatic onset in PEG-treated
EAE mice was 20.63 ± 1.8 days, which was delayed significantly relative to shamtreated EAE mice (15.42 ± 0.4 days, P < 0.05) (Fig 4.2).
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Figure 4.2 Evaluation of PEG as a Therapy for EAE Axonal Damage.
Comparison of behavioral assessment each day between EAE (n =12) and PEGtreated (n=11) groups. The graph represents the average score for each group
of animals throughout the study. The inset demonstrates that administration of
PEG significantly decreased the severity of symptoms in EAE mice (P < 0.005).
The highest score of each animal was recorded and averaged within each group
to quantify the mean score of severity to be used for the inset.
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Figure 4.3 PEG Delayed Symptom Onset in EAE Mice. Comparison of onset of
symptoms between EAE (n=12) and PEG-treated (n=11) groups. The graph
represents the temporal distribution and the day of onset of symptoms between
EAE and PEG-treated mice. On the first day symptoms appeared, the number of
mice in each group was recorded. The EAE mice were tightly clustered together
earlier in the study while the PEG-treated mice were more dispersed. The inset
graph represents the average day of onset for EAE and PEG-treated groups.
PEG-treated animals developed symptoms significantly later in the study
compared to EAE mice (P < 0.01). Three mice in the PEG-treated group never
developed symptoms and were counted as day 28 for both graphs.

4.4

Discussion

Using the HRP-exclusion assay to quantify axolemma permeability, we
have verified axonal membrane damage is greatest when symptoms are at their
peak severity [78, 79, 86]. Also, although not as robust, axonal membrane
permeability was significantly increased even in pre-symptomatic EAE mice,
indicating that axonal membrane damage is indeed a critical component underlying
the development of EAE (Fig 4.1).
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Furthermore, the daily application of the membrane sealing agent PEG,
elicited a significant reduction in axolemma injury as indicated by decreased
membrane permeability following the HRP assay relative to the sham-treated
group (Fig 4.1) [84, 85, 87]. Along with the neuroprotective effect afforded to
axons, PEG treatment also delayed symptomatic onset and reduced severity of
behavioral deficit (Fig 4.2, 4.3).

In light of these findings, it is evident that

axolemma injury is a critical component of the EAE pathology and partly underlies
functional impairment. Additionally, we have identified a way to repair damaged
axons using PEG to facilitate membrane resealing, prevent neuronal loss and
ameliorate behavioral deficit characteristic of EAE.
These results suggest that administration of PEG to EAE mice is
neuroprotective due to its ability to repair axolemma in vivo, effectively promoting
cell survival and reducing the risk of axon degeneration [2, 76, 88]. Membrane
integrity is critical to the maintenance of ionic gradients necessary for generating
action potentials and to prevent the influx of calcium into the cell [79, 89, 90]. It is
hypothesized that membrane repairing agents also have the potential to curtail
mitochondrial dysfunction seen in MS by way of preventing noxious compounds
from entering the cells, disrupting the electron transport chain and perpetuating
oxidative stress. In this way PEG is neuroprotective in EAE mice through both
direct and indirect mechanisms [41, 46, 82, 87, 91, 92].
We also observed a significant degree of increased membrane permeability
in pre-symptomatic mice that were subjected to HRP analysis seven days before
the emergence of symptoms. Therefore, axonal membrane injury processes
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precede the onset of motor deficit by at least seven days. The preservation of
motor function despite evidence of significant axonal membrane damage in EAE
mice can be attributed to the plasticity of the nervous system. Since there appears
to be a certain degree of axon loss associated with symptomatic onset, there is
potential to use axonal membrane damage markers to determine when symptoms
will emerge.
Since application of PEG promotes axonal membrane resealing, it is
feasible to suggest its synergistic use with other therapeutic approaches such as
immunosuppression and alleviation of oxidative stress. Due to the link between
myelin, axolemma and mitochondrial damage underlying this pathology, it may
prove beneficial in employing therapeutic strategies to address both demyelination
and axonal membrane damage, both of which will indirectly protect CNS
mitochondria from insult by extracellular compounds. The potential success of
using PEG in combination with an immunosuppressant or acrolein scavenger can
be attributed to PEG’s ability to repair existing damage coupled with another
compound aimed at removing key mediators of inflammation and oxidative stress.
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CHAPTER 5. ESTABLISHMENT OF ACROLEIN DETECTION METHODS

5.1

Introduction

Given the aforementioned evidence of the neurotoxicity and pathological
role of acrolein in MS, development of new methods of monitoring acrolein in vivo
is crucial if acrolein research is to be translated to a clinical setting. Success in this
endeavor could also potentially facilitate the establishment of acrolein as a
biomarker for diagnosis, guiding treatment regimens and monitoring relapses by
elucidating dynamics of acrolein levels in different phases of MS. Recent
advancements have been made in acrolein detection enabling quantification of
systemic acrolein levels through the evaluation of a urine or serum sample. The
following sections serve as a brief overview of currently available acrolein detection
techniques.
5.1.1 Gas Chromatography (GC) and Liquid Chromatographay/Mass
Spectrometry (LC/MS)
Acrolein detection research began with studies conducted in the 1960s
which primarily consisted of studies of environmental pollution and exposure to
pollutants [93]. Acrolein exposure by way of pollutants such as car exhaust,
industrial processes and cigarette smoke occurs on a much larger scale than
endogenous exposure following disease or trauma, allowing for the direct
quantification of acrolein with gas chromatography (GC) or liquid chromatography
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followed by mass spectrometry (LC/MS) and subsequent derivatization steps [9496]. While suitable for exogenous exposure studies, GC and LC/MS-based
techniques are not the preferred method for endogenous acrolein detection,
primarily due to the highly reactive nature and substantially lower concentrations
of acrolein [49].
5.1.2 Antibody Detection of Acrolein-Protein Adducts
Considerable developments in endogenous acrolein detection were made
by Uchida and colleagues, who introduced acrolein-protein adduct antibodies and
enabled quantification of small changes in endogenous acrolein levels [97]. When
used in conjunction with Western blotting, these antibodies afford insight into the
interactions of acrolein with different proteins. However this method is not preferred
when endogenous acrolein is present extremely low concentrations; in this
situation dot immunoblotting is employed [44, 98].
The advantage of dot immunoblotting lies in the ability to enhance signal
strength by combining all detected acrolein-protein adducts into one focus [56, 98].
The increased sensitivity afforded by this technique, renders it ideal for
quantification of acrolein produced by endogenous processes. Additionally,
accuracy is also improved in this technique due to simultaneous analysis of
artificial acrolein standards and samples. In relation to the current study dot
immunblotting is the preferred method for the assessment of CNS acrolein levels
in animal studies.
It is important to note that although these techniques are useful in a
preclinical research setting, their clinical applicability is not feasible. This can
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primarily be attributed to the highly invasive nature of antibody-based techniques
since a biopsied sample of the tissue of interest is required.
5.1.3 3-Hydroxypropyl Mercapturic Acid (3-HPMA) detection with LC/MS/MS
The pursuit of new acrolein detection techniques is vital if acrolein research
is to be translated to a clinical setting, as there is a need for minimally invasive
techniques to conduct a thorough investigation of the role of acrolein in clinical
cases of MS. One of the most promising emerging acrolein detection strategies is
the 3-hydroxypropylmercapturic acid (3-HPMA)-based method [99, 100]. This
approach is contingent upon the quantification of an acrolein metabolite in either a
urine or serum sample of a patient. Level of 3-HPMA, a unique acrolein-GSH
metabolite, is indicative of systemic acrolein levels [101]. The main advantage of
this approach centers around noninvasive nature, when using a urine sample or
its minimally invasive nature, for serum samples [100]. Furthermore, 3-HPMA
quantification techniques utilize LC/MS/MS, presenting the possibility for
automation and miniaturization for ease of use in clinical acrolein detection [102].
The main disadvantage of this technique is that it does not offer insight as
to the cause of an increase in acrolein levels since it is a systemic quantification.
Also when GSH is inadequate, as it is in many instances of CNS disease and
trauma, 3-HPMA may not reflect the true acrolein level since there is not a sufficient
amount of glutathione for acrolein to react with to yield 3-HPMA.

This notion is

supported by a study conducted by Shi and colleagues in which as higher dosages
of acrolein were administered to SCI rats, GSH was consumed and a decline in 3HPMA level was observed [56, 100]. Additionally, since acrolein can react with a
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wide variety of biomolecules, not only GSH, 3-HPMA quantification strategies
could potentially underestimate actual systemic acrolein levels.
5.1.4 Translational Nature of Acrolein Research
Due to recent advances in acrolein detection techniques, minimally invasive
quantification of systemic acrolein levels can be achieved through the
measurement of 3-HPMA, a specific acrolein-glutathione metabolite, in urine and
serum using LC/MS/MS. In contrast to previous methods utilized exclusively in
animal studies, which required animal euthanization to harvest fresh CNS tissue,
this approach allows for the longitudinal assessment of acrolein levels and thus
facilitates the translation of acrolein research to clinical scenarios. Collectively, this
evidence suggests the potential of acrolein as not only a therapeutic target for MS
patients, but also as a biomolecule that could potentially be monitored to aid in
diagnosis, predict disease course, and guide treatment regimens on a patient-bypatient basis.
5.2

Materials and methods

5.2.1 Animal Preparation
Rodent studies were conducted in accordance with guidelines mandated by
the Purdue Animal Care and Use Committee at Purdue University, West Lafayette,
IN, USA. Eight-week-old C57BL/6 female mice (Harlan Laboratories, Indianapolis,
IN, USA) were maintained in laboratory animal housing facilities for two weeks
prior to EAE induction to minimize potential effects of stress.
5.2.2 EAE Model Induction and Behavioral Assessment
See 3.2.1 and 3.2.2
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5.2.3 Dot Immunoblotting
Spinal cords were harvested from mice following exsanguination and
perfusion of oxygenated Kreb’s solution as described in prior publications. The
fresh tissues were incubated with 1% Triton solution and Protease Inhibitor
Cocktails, (Sigma-Aldrich, Product #: P8340) homogenized (Kontes Glass Co.)
and incubated on ice for at least 1 hour. Samples were then centrifuged at 13,500
g and 4 °C for a minimum of 30 minutes.
BCA protein assay was performed to ensure equal loading for all samples.
Samples were transferred to a nitrocellulose membrane using a Bio-Dot SF
Microfiltration Apparatus (Bio-Rad, Hercules, CA, USA). The membrane was
blocked for 1 h in blocking buffer (0.2% Casein and 0.1% Tween 20 in PBS) and
transferred to a solution where polyclonal rabbit anti-acrolein antibody (Novus
Biologicals) was dissolved, with a ratio of 1:1000, in blocking buffer with 2% goat
serum and 0.025% sodium azide, for 18 h at 4 °C. The membrane was then
washed blocking buffer and incubated for 1 hr in a solution of 1:10,000 alkaline
phosphatase conjugated goat anti-rabbit IgG (VECTASTAIN ABC-AmP Kit). Final
washes of the blocking buffer followed by 0.1% Tween 20 in Tris-buffered saline
were performed before the membrane was exposed to substrate of the ABC-AMP
kit and visualized by chemilluminescence. Band density was quantified using
Image J (NIH) and expressed as arbitrary unit.
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5.2.4 Animal Urine Collection
Mice were housed in metabolic cages, designed to obtain urine samples,
for 12-24 hours. Regular food and water were supplied during the sample
collection period. Samples of approximately 500 ml were obtained from each
animal at peak behavioral deficit between days 21-23. Samples were then
transferred to 1 ml centrifuge tubes and frozen at -80 °C until biochemical analyses
were performed.
5.2.5 Subject Enrollment
All human specimens were collected at the Department of Neurology,
Indiana University School of Medicine, Indianapolis, IN, USA by Dr. David Mattson
and colleagues. Criteria for subject selection consisted of an MS diagnosis
provided that the patient was not be receiving corticosteroids at the time of the
sample collection. In this regard, it is important to note that many patients were on
various FDA-approved MS immunotherapies at the time of sample collection. This
study was carried out in accordance with guidelines set forth in the protocol
approved by the Indiana University Human Subjects Institutional Review Board.
5.2.6 Clinical Urine Collection
Subjects were provided with a specimen cup, without preservative, for urine
sample collection. Urine samples were then pipetted into labeled cyrovials and
immediately stored at -70 °C prior to being transported to Purdue University on dry
ice. Upon arrival, samples were immediately stored at -80 °C until analysis.
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5.2.7 Clinical Serum Collection
Venous blood samples were then obtained (BD Vacutainer® Safety-Lok™
Blood Collection Set 23, Gauge 3/4 Inch Safety Needle, 12 Inch Tubing Sterile)
and directly placed into a BD Vacutainer® Plus Venous Blood Collection Tube
Serum Tube Clot Activator 13 X 100 mm 6 mL BD Hemogard™ Closure Plastic
Tube. Following collection, samples were incubated for 15 minutes at room
temperature to facilitate clotting. The samples were then centrifuged at 2800 rpm
for 15 minutes (Beckman GS-6R) and transferred to a labeled cyrovial and stored
at Thermo Scientific -70 °C. Samples were then transported to Purdue University
on dry ice and stored at -80 °C until analysis.
5.2.8 3-HPMA Quantification Using LC/MS/MS and standard preparation
3-HPMA was quantified in urine according to Eckert et al (Eckert, Drexler et
al. 2010). Solid phase extraction with Isolute ENV+ cartridges (Biotage, Charlotte,
NC) was used to prepare each sample before LC/MS/MS analysis. Cartridges
were conditioned with 1mL of methanol, 1mL of water, and 1mL of 0.1% formic
acid in water in succession. Urine or serum sample aliquots of 500 µL were
combined with 200 ng of deuterated 3-HPMA (d3-3-HPMA) (Toronto Research
Chemicals Inc., New York, Ontario), 500 µL of 50 mM ammonium formate and 10
µL of undiluted formic acid and pipetted into the prepared ENV+ cartridges. The
cartridges were then washed twice with 1 mL of 0.1% formic acid and 1 mL of 10%
methanol/90% 0.1% formic acid in water in succession. The cartridges were dried
with nitrogen gas and subsequently eluted with three volumes of 600 µL methanol
+ 2% formic acid which were combined and dried in a rotary evaporation device.
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Samples were reconstituted in 100 µL of 0.1% formic acid prior to LC/MS/MS
analysis.
Quantification of 3-HPMA in the samples was determined using an Agilent
1200 Rapid Resolution liquid chromatography (LC) system coupled to an Agilent
6460 series QQQ mass spectrometer (MS) and a Waters Atlantis T3 2.1mm x
150mm, 3 µm column for LC separation. Water + 0.1 % formic acid and acetonitrile
+ 0.1% formic acid were used as buffers. The peak retention time of 3-HPMA/d33-HPMA was 6.8 minutes. Multiple reaction monitoring was used for MS analysis.
A more detailed procedure is outlined in previous publication (Zheng 2013).
Creatinine quantification was performed to provide an internal standard
normalize urine 3-HPMA measurements. Sample creatinine concentrations were
determined through the use of a urinary creatinine assay kit (Cayman Chemical
Company, Item No. 500701). Urine samples were diluted for 12x and 24x prior to
measurement and alkaline picrate solution was prepared following the procedure
delineated in the assay manual. The diluted samples and creatinine standards
were then loaded into a 96 well plate and incubated with the alkaline picrate
solution at room temperature for 20 minutes. Absorbance at 490-500 nm was
determined using a standard spectrophotometer and the results were recorded as
the initial reading. Following the initial reading, 5ul of acid solution was added to
each sample and incubated on a shaker at room temperature for an additional 20
minutes. A spectophotometer (absorbance at 490-500 nm) was used again to
determine the final reading following addition of the acid. The differences between
the initial and final absorbance measurements were used for quantitative analysis.
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BCA assessment was used as a normalization factor for the serum 3-HPMA
measurements. Protein concentrations using bovine serum albumin were
quantified using the Bicinochoninic Acid protein assay kit (Pierce, Rockford, IL,
USA). Serum samples were prepared in a 1:100 dilution and loaded into a 96 well
plate along with BCA standards in triplicates. BCA reagent was then added to all
wells and the samples were incubated at 37 C for 30 minutes. Following incubation
the absorbance of the samples at 560-570 nm was determined using
SPECTRAMAX (Molecular Devices, Sunnyvale, CA, USA).
5.3

Results

5.3.1 CNS and Systemic Elevation of Acrolein in EAE Mice
Urine was collected from EAE mice (n=9) and controls (n=9) when peak
deficit occurred at days 21-23 (Fig 5.1).
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Figure 5.1 Behavioral Deficits Following MOG EAE Induction. The motor
deficits typical of EAE were scored daily for 4 weeks. The average value
(and SEM) is plotted against time post induction. The shaded area
indicates the time period when urine 3-HPMA were collected and assessed
using LS/MS and acrolein-lysine adduct of spinal cord tissue were used
through dot blot, both assessing acrolein levels. Note the steady rises of
EAE score beginning at around 11-12 days and reaches peak around 2122 days post induction. Data expressed as average ± SEM.
Systemic acrolein levels were determined through the quantification of 3HPMA in urine samples using LC/MS/MS. EAE mice demonstrated significantly
elevated urine 3-HPMA levels relative to their healthy counterparts (Fig 5.2). Both
groups were sacrificed at day 28 and spinal cord tissue was harvested to assess
local acrolein concentrations within the CNS using an immunoblotting assay.
Measurements of acrolein in the CNS corresponded to the results obtained from
3-HPMA analysis of the urine, in which EAE mice exhibited significantly elevated
intrinsic levels of acrolein-lysine adducts relative to the control group (Fig 5.3).
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Figure 5.2 Determination of Acrolein Concentration Through Urine 3-HPMA
Measurement in EAE Mice. . (A). Chemical reaction of acrolein with glutathione
(GSH) and production of subsequent metabolites OPMA and 3-HPMA. (B). Bar
graph depicts the ratio of 3-HPMA and creatinine measured in urine of control
and EAE mouse. Urine samples were collected approximately 21-23 days after
MOG injection in EAE mouse when the behavior deficits peak. Each urine
sample represents an accumulative volume of a 24 hr period. Age matched mice
served as controls. Note the increase of 3-HPMA in urine in EAE. (P < 0.05
when compared to control, t-test). N = 5 in each group of 3-HPMA measurement
in urine. Data expressed as average ± SEM.

51

Figure 5.3 Elevations of CNS Acrolein Concentrations in EAE Mice. The
acrolein-lysine adducts in control and in EAE were detected using Bio-Dot
SF microfiltration apparatus. Band intensity were analyzed using image J
(NIH) are expressed in arbitrary units. Note the Bar graph demonstrated
the increase of acrolein-lysine adducts in EAE. (P < 0.05 when compared
to control, t-test). N = 4 in each group of acrolein measurement in tissue.

5.3.2 Multiple Sclerosis Patients Exhibited Increased 3-HPMA in Urine and
Serum
Urine and serum samples were collected from diagnosed MS patients
(urine: n=40; serum: n=41) and volunteer controls consisting of mainly office staff
and family members of patients (urine: n=23; serum n=23). Acrolein content within
the specimens was reflected through the assessment of 3-HPMA using
LC/MS/MS. Figure 5.4 depicts 3-HPMA measurements as both an mean value and
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as a scatter plot to show distribution of urinary 3-HPMA levels within the group.
Mean 3-HPMA levels detected in the urine of MS patients were significantly
elevated relative to healthy controls. Furthermore, multiple patients exhibited
urinary 3-HPMA levels that exceeded the maximum 3-HPMA level detected in the
control group. Results obtained following quantification of 3-HPMA in patient
serum specimens corresponded with the values obtained from urine analysis for
both the MS group and the control group, in which MS patients demonstrated a
significant elevation compared to control (Fig 5.5). The scatter plot also shows a
similar distribution of the data in which a number of MS patients exceeded the
maximum serum 3-HPMA value obtained from the control group. Interestingly, a
correlation analysis between 3-HPMA measurements in MS patient urine and
serum samples, revealed a significant positive relationship (Fig 5.6).
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Figure 5.4 Determination of Acrolein Concentration Through Urine 3-HPMA
Measurement in MS Patients and Healthy Individuals. The MS patient group
including relapsing-remitting (RR), primary progressive (PP), and secondary
progressive (SP) types of MS. (A). Bar graph demonstrate the average value of
urine 3-HPMA. Specifically, the average concentration of 3-HPMA is 1.094±0.212
μg/mg creatinine for MS patients (N = 40) and 0.570±0.082 μg/mg creatinine for
healthy individuals (N = 23). Note the increase of 3-HPMA in urine in MS
patients. (: P < 0.05 when compared to control, t-test). Data expressed as
average ± SEM. (B). A scatter plot of the same data used in (A), including all the
data points to reveal the range and distribution of measured values. Solid lines
indicate the average of 3-HPMA in both MS and healthy control individuals. Note
that while many data points of MS patients were distributed in the same range as
that of control, there were still multiple points of MS were greater than that in
control, some by multiple folds
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Figure 5.5 Determination of Acrolein Concentration Through Serum 3-HPMA
Measurement in MS Patients and Healthy Individuals. The MS patient group
including RR, PP, and SP types of MS. (A). Bar graph demonstrate the average
value of serum 3-HPMA. Specifically, the average concentration of 3-HPMA is
0.065±0.009 μg/g protein for MS patients (N = 41) and 0.036±0.004 μg/g protein
for healthy individuals (N = 23). Note the increase of 3-HPMA in serum among
MS patients. ( : P < 0.01 when compared to control, t-test). Data expressed as
average ± SEM. (B). A scatter plot of the same data used in (A), including all the
data points to reveal the range and distribution of measured values. Solid lines
indicate the average level of acrolein in both MS patients and control individuals.
Note that while many data points of MS patients were distributed in the same
range as that of control, there were still multiple points of MS were greater than
that of control, some by multiple folds.
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Figure 5.6 Correlation of 3-HPMA Levels in Urine and Serum in MS patients. The
urine 3-HPMA is plotted against serum 3-HPMA for 39 MS patients showing the
relation between these two parameters. Urine and serum were collected at the
same time for all patients. As indicates, the increase of urine 3-HPMA seems to
accompanied by the elevation of serum 3-HPMA. Statistical analysis of
correlation revealed A Pearson correlation coefficient r-value of 0.75, (p<0.0001,
two tailed).

5.4

Concluding summary

The 3-HPMA detection method is a significant advancement in the field of
acrolein research and allows investigators to quantify endogenous acrolein levels
in clinical scenarios. Furthermore, since 3-HPMA is a specific adduct for acrolein
and GSH, 3-HPMA elevations can only be attributed to an increase in endogenous
acrolein concentration. Prior to the establishment of this method, endogenous
acrolein research in the CNS was largely limited to animal studies due to the
invasive nature of other acrolein quantification methods, which require a fresh
tissue sample. In a prior study, we reported acrolein elevations in the spinal cord
tissue of EAE mice and that the application of an acrolein-scavenger, hydralazine,
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effectively reduced acrolein levels, delayed symptom onset and reduced severity
of motor deficits (Leung 2011). However, to our knowledge, urine 3-HPMA
quantification has not been previously employed in the EAE model to assess
systemic acrolein levels.
In the current study, when EAE mice exhibited peak deficit (days 21-23),
urine samples were collected from both EAE and control groups. At the study
conclusion (day 28) mice were euthanized and spinal cords were harvested for
assessment of acrolein-lysine adducts to verify the 3-HPMA method.
Concordantly, EAE mice exhibited elevated 3-HPMA and acrolein levels relative
to control mice. The success of non-invasive acrolein detection in urine permits
longitudinal in vivo studies of acrolein dynamics, evaluation of anti-acrolein
therapies and, most notably, detection of acrolein in human patients. As acrolein
has already been established as a novel therapeutic target in EAE, the current
study was primarily intended at investigating the pathological role of acrolein in
clinical cases of MS.
The clinical component of this study exclusively relied on 3-HPMA
quantification as an acrolein detection method, however 3-HPMA was
independently quantified in both urine and serum samples to ensure the reliability
of the measurements. In both urine and serum, mean 3-HPMA was significantly
elevated in MS patients relative to controls indicating that acrolein may play a
similar role in EAE and MS and the acrolein-scavenging in MS patients could
potentially have therapeutic benefit. Interestingly, 3-HPMA concentration in urine
was an order of magnitude greater than that detected in serum samples. This
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discrepancy can potentially be attributed to a larger total volume of serum than
urine and also that as acrolein is removed from circulation by the renal system,
excreted waste is more concentrated.
Clinical detection of increased acrolein levels in MS not only implicates acrolein
as a pathological target, but also prompts further investigation of the utility of
acrolein as a biomarker for diagnosis, disease monitoring and guiding therapeutic
regimens. As previously discussed, acrolein is primarily a clinical diagnosis
supplemented by neuroimaging and other laboratory tests. However, the presence
of MS symptoms accompanied by an elevated acrolein level may potentially allow
a physician to establish an MS diagnosis in the future from a thorough history,
physical exam and a collection of a urine sample. Additionally, acrolein may also
have clinical applicability as a biomarker to predict relapses or clinical progression
in later stages of the disease in which remission no longer occurs. To investigate
acrolein as a potential biomarker for disease monitoring, additional clinical studies
are needed to examine acrolein at multiple time points in the same patient,
particularly shortly prior to and during relapses when MS is in an active stage.
If 3-HPMA elevations are observed prior to development of new symptoms,
then there is potential for acrolein scavengers to be administered in an effort to
decrease severity or latency of the relapse. Acrolein detection would also enable
a more personalized approach to the treatment of MS. As can be observed in the
scatter plots (Figure 5.4, 5.5), some MS patients exhibited 3-HPMA values that did
not appear to be significantly elevated relative to controls. While it is possible that
these patients were not exhibiting acrolein elevations due to remission, it raises
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the plausibility that some MS patients may not benefit from anti-acrolein therapy.
Non-invasive acrolein detection also allows for dosage of acrolein scavengers to
be tailored to a specific patient. In summary, the noninvasive 3-HPMA detection
method and availability of FDA-approved compounds capable of scavenging
acrolein, hydralazine and phenelzine, underscores the translational nature of
acrolein research which could potentially revolutionize current therapeutic
approaches to the treatment and management of MS.
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CHAPTER 6. RESPIRATORY EXPOSURE TO ACROLEIN

6.1

Introduction

Acrolein is exogenously present as a pollutant generated by the incomplete
combustion of wood, petrol and plastic, industrial processes, smoking of tobacco
products and frying of foods in oil [48]. Similarly to acrolein produced
endogenously, environmental sources of acrolein have the potential to be
systemically absorbed by the body and thus can react with biomolecules and inflict
damage to virtually every organ system [103]. In fact, environmental acrolein
exposure, particularly in the case of cigarette smoking, can elicit 3-HPMA
elevations in urine that are two times greater than the level seen in non-smokers
and upon cessation of smoking, 3-HPMA levels declined by approximately 78%
[104]. The amount of acrolein generated by burning cigarettes is highly dependent
on the glycerin content, which varies from brand to brand, however acrolein is
estimated to be present in concentrations of 56-69 μg in one cigarette [105].
Detrimental effects of cigarette smoking are well characterized and vast, as
tobacco use has been linked to many pathologies spanning all the major organ
systems. In fact, clinical cohort studies have reported that exposure to cigarette
smoke directly, indirectly, and even in early life seems to be exacerbating the
development and progression of MS functional loss [7, 10, 106-109]. However, the
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pathophysiological mechanisms underlying this relationship remain elusive and
the individual compound(s) within cigarette smoke that are contributing have yet
to be ascertained. In a previous study aimed at assessing the impact of tobacco
use through both inhalation and oral routes, have found no apparent association
between oral tobacco use and MS, indicating that nicotine does not play a role.
Therefore a compound in tobacco, other than nicotine, that is present in greater
concentrations upon burning appears to be the culprit [110]. Due to the established
connection between MS and endogenous acrolein levels, the association between
MS and exogenous acrolein exposure, specifically through inhalation when
smoking or in close proximity to smokers, warrants further investigation.
6.1.1 Cigarette Smoking in Humans
As the single most preventable cause of death, cigarette smoke is a
universally known environmental pollutant, producing a array of harmful chemicals
that are detrimental to human health leading to various illnesses or death [111].
Exposure occurs through primary and secondary sources that few can avoid in our
modern society given that one in five adults in the US are current cigarette smokers
[21, 111]. Specifically relating to our interests, cigarette smoke is suspected of
exacerbating multiple sclerosis and other neuropathologies as evidenced by
recent clinical and laboratory observations [7, 10, 106-109]. This concern is further
fueled by taking into consideration that patients with neurological disabilities tend
to be more avid, heavier smokers, who are less likely to quit compared to general
population [111].
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Acrolein is endogenously elevated in animal models and clinical cases of
MS and also is an emission component of tobacco smoke [56, 105]. It has been
demonstrated that systemic and CNS acrolein levels increase following respiratory
exposure to acrolein [104, 112]. Due to its neurotoxic nature, its commonality
between MS and tobacco emissions, and epidemiological studies linking MS and
cigarette smoking, it is possible that acrolein is capable of accumulating from
environmental exposure and worsening clinical course for MS patients who smoke
tobacco. In order to further study this relationship, an animal model for acrolein
inhalation was established and preliminary animal studies were conducted to
ascertain the relationship between respiratory acrolein exposure and accumulation
both systemically and locally within the CNS.
6.1.2 Acrolein Inhalation in Mice
To further investigate the effect of respiratory acrolein exposure in the CNS,
it is imperative to determine if inhalation of exogenous acrolein can affect
endogenous systemic 3-HPMA levels detected by LC/MS/MS in a controlled
animal study. The current study was preformed to examine the hypothesis that
acute respiratory exposure to acrolein can evoke an increase in endogenous
acrolein levels. More specifically, since MS is a disease of the CNS, the ability of
acrolein to accumulate in the brain and spinal cord following respiratory exposure
could have serious implications in the understanding clinically reported links
between cigarette smoking and MS. Following respiratory exposure to acrolein at
a concentration relevant to that in cigarette smoke for three weeks, urinary 3HPMA and acrolein-lysine adducts in the spinal cord were both increased relative
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to the sham and control groups. This data is indicative that acrolein is capable of
systemic absorption through the pulmonary circulation and, furthermore, can cross
the blood brain barrier to infiltrate the CNS.
6.2

Materials and methods

6.2.1 Respiratory Exposure to exogenous acrolein
An air-tight chamber made of plexiglass (10 in. x 14 in. x 6 in.) was made in
our laboratory and placed in a ventilation hood (Fig. 6.1). A compressed gas
cylinder containing an acrolein air mixture of ~350ppm (Praxair, Geismar, LA,
USA) was adjusted by delivering controlled volumes of ambient air from a
compressed gas cylinder (Indiana Oxygen, IN, USA) using two flowmeters
(Aalborg, Orangeburg, NY, USA). The diluted acrolein:air mixture was then forced
into the chamber through an input valve. Exhaust from the chamber was expelled
through an output valve and passed through an activated charcoal filter (VetEquip,
Pleasanton, CA, USA) within the ventilation hood. Final delivered concentration in
the current study was 1.5 ppm acrolein in air, a concentration verified using
GC/MS. Gas samples from the chamber were obtained using a vacutainer (BD,
Franklin Lakes, NJ, USA) and GC/MS analysis was carried out as outlined below.
Mice were divided into three groups: control, sham, and acrolein. The
control group were not exposed to the inhalation chamber. Animals from the sham
group were placed in the chamber and received a controlled volume of ambient
air, while the acrolein group was exposed to 1.5 ppm acrolein in air. Exposure
paradigm for the sham and acrolein mice was 30 minute sessions, twice a day, for
an observation period of three weeks.
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6.2.2 Gas chromatography/Mass Spectrometry
A Pegasus 4D gas chromatography/gas chromatography time-of-flight
mass spectrometer (GCxGC/TOF-MS, LECO Corporation, St. Joseph, MI), with a
CTC CombiPAL autosampler (LEAP Technologies, Carrboro, NC) was used for
sample analysis. Prior to injection, samples (0.5 mL) were agitated for 5 minutes
at 80°C and 500RPM. An Rtx-65 capillary column (Restek, 30 m x 0.25 mm x 0.25
um) and high purity helium (carrier gas, 1.0 ml/min, 10:1 split ratio) were selected.
Temperature program was set to begin at 40°C (3 minute hold time) and then
increased to 140°C at a rate of 20°C/min. Temperature for the injection inlet
temperature and the mass spectrometer transfer line were set to 130°C and 200°C,
respectively. The electron impact ion source was maintained at 200 °C and
filament bias was -70 V. Mass spectra were obntained from 23 to 200 m/z at 30
spectra/sec. Acrolein standards ranging from 33 and 3300 ppm were prepared
and mass peaks of 55 and 56 were used for acrolein quantification. Acrolein
retention time was 107 sec.
6.2.3 Detection of Acrolein-Iysine Adducts Dot Immubloting
See 5.2.3
6.2.4. 3-Hydroxypropl Mercapturic Acid (3-HPMA) Quantification
See 5.2.8
6.2.5 Subject Recuritment\
See 5.2.5
6.2.6. Clinical Urine Collection
See 5.2.6
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6.3

Results

6.3.1 Urine 3-HPMA/Creatinine Levels Increased Following Acrolein Inhalation
in Mice
Urine samples were obtained at 0 (before inhalation), 1, 2, and 3 weeks
post inhalation to determine the ability of acrolein to accumulate systemically and
locally following respiratory exposure. Using LC/MS/MS urinary 3-HPMA levels
were measured and the current data suggests a direct relationship between urine
3-HPMA concentration and duration of acrolein exposure. In other words, 3-HPMA
levels were observed to steadily increase over the three week observation period
(Fig 6.1 C). A significant elevation was observed from baseline (11.46 ± .05 µg/mg)
in measurements taken at both week 2 (14.43 ± 0.84 µg/mg, p<0.05) and 3 (17.82
± 0.33 µg/mg, p<0.01). A significant increase was also detected between week 1
(12.41 ± 1.85 µg/mg, p<0.05) and week 3. Mice from the sham group did not
demonstrate significant changes in urine 3-HPMA for the duration of the study.
6.3.2 Respiratory Acrolein Exposure Increases Acrolein-Lysine in Mouse Spinal
Cord Tissue
At the study conclusion, fresh spinal cords were harvested for quantification
of acrolein-lysine adducts to assess acrolein accumulation in the CNS. A dot
immunoblotting assay was conducted using the spinal cord samples from the three
experimental groups: acrolein, sham, and control (Fig 6.1 D). Acrolein-lysine
adduct level in the spinal cords of mice following acrolein respiratory exposure for
three weeks (10.56 ± 0.59 a.u.) was significantly increased compared to the sham
group (3.71 ± 0.58 a.u., p<0.05), or control group (4.52 ± 1.97 a.u., p<0.05).
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Figure 6.1 Preclinical Assessment of the Effects of Respiratory Acrolein
Exposure in Mice. .(A) Acrolein reaction with glutathione and production of
subsequent metabolites OPMA and 3-HPMA. Bottom: Mass spectra outputs of
d3-3-HPMA (Standard) and 3-HPMA measurements obtained from mouse urine.
(B) Metabolic cage used for urine collection. (C) Bar graph displaying the ratio of
3-HPMA and creatinine measured in urine of acrolein-inhaled mouse at day 0
(11.46±0.50), day 7 (12.41±1.85), day 14 (14.43±0.84), and day 21(17.82±0.33)
of acrolein exposure (acrolein group: Filled bars). 3-HPMA concentrations for the
sham group were at day 0 (11.80±1.57), day 7 (11.29±1.17), day 14
(11.09±1.34), and day 21(12.02±2.02) (sham group: open bars). ANOVA
comparisons among acrolein group yielded p < 0.05 between days 0 and 14, and
days 7 and 21; p<0.01 between days 0 and 21. No significance were found within
sham group. Values are expressed as mean SEM. N = 5-10 in all conditions.
(D)Dot immunoblotting results comparing levels of acrolein-lysine adducts in the
spinal cord tissue of animals from each of the three groups. Bar graph displays
that the acrolein-lysine levels in acrolein group (10.56 ± 0.59 a.u.) is significantly
higher than those in sham group (3.71 ± 0.58 a.u.), and control group (4.52 ±1.97
a.u.,) (n=4 in all groups, ± P < 0.05, ANOVA). Values are expressed mean ±
SEM. (E)Diagram of inhalation setup.
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6.3.3 Systematic 3-HPMA Elevation in MS Patients Who Are Self-Reported
Cigarette Smokers
MS patients who identified as tobacco smokers, exhibited drastically
increased 3-HPMA levels (7.1±2.9; n=6) relative to non-smoker MS patients
(1.094±0.212; n=40; P<0.05) (Fig 6.2). Furthermore, MS smokers exhibited
significantly elevated EDSS scores (4.25+/- 1.03; n=6) compared to MS
nonsmokers (1.55+/- 0.39; n=40; P<0.05) (Figure 6.3). We hypothesize that the
drastic increase is the result of an additive effect of respiratory exposure to
acrolein, as a result of tobacco smoking, combined with pathologically elevated
levels of acrolein resulting from oxidative stress. These clinical findings support
data obtained in preclinical studies and provide further evidence that acrolein
research is translational and data currently being obtained using the EAE model
has high potential to be clinically applicable in MS patients.
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Figure 6.2 Smoking in MS Patients is Associated with Higher Urine 3-HPMA

Figure 6.3 Smoking Cigarettes is Associated with Higher EDSS Scores in
Multiple Sclerosis Patients.
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6.4

Discussion

The current study concludes that exposure to acrolein in the respiratory
system results in systemic absorption of acrolein and infiltration of acrolein into the
CNS across the blood brain barrier. Specifically, an increase in the acrolein-GSH
metabolite, 3-HPMA, can be elicited in a controlled animal model following acrolein
respiratory exposure at a concentration relevant to that in cigarette smoke.
Furthermore, local concentrations of acrolein in the CNS were found to be elevated
in mice as indicated by acrolein-lysine adduct levels within the spinal cords of
animals that inhaled acrolein. These findings are consistent with previous clinical
observations, which reported that human cigarette smokers exhibited higher levels
of urine 3-HPMA by 5-10 times when compared to nonsmokers [104, 113].
However, subject smoking histories were significantly longer than the three week
period modeled in this study, with most patients reporting regular cigarette
consumption over a period of years. Due to the constraints of clinical studies,
primarily limited to retrospective cohort investigations, an adequate quantification
study correlating aerosolized acrolein dosage and urine 3-HPMA level has not
been conducted. The main advantage in the current study is the use of an animal
model permits control of experimental conditions, such as the concentration,
duration and paradigm of acrolein exposure.
Acrolein was shown to be effectively absorbed upon inhalation for no more
than two weeks and aggregated in the blood stream, increasing 3-HPMA levels by
30% after two weeks and 60% after three weeks of exposure (Fig 6.1 C).
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An acrolein concentration of 1.5 ppm was selected for the current study because
of its use in previous animal studies, it is significantly lower than reported acrolein
concentration in tobacco smoke and is well above the concentration of acrolein in
ambient air, which may render it applicable in future studies examining acrolein
accumulation following second-hand tobacco smoke exposure [114-121]. The
exposure paradigm of two 30 minute exposures per day was employed in an
attempt to mimic smoking a half a pack or 12 cigarettes per day. This rough
calculation was based on the assumption that a cigarette burns for 5 minutes and
the total daily 60 minute exposure time was adjusted to be two 30 minute
exposures to allow animals to recover following acrolein inhalation and minimize
acute toxicity.

In a 2010 report, the CDC estimated that the average American

tobacco user smokes 20 cigarettes daily indicating that if this estimation is correct,
mice were exposed to less acrolein daily than the average smoker.
Increase in 3-HPMA level following respiratory acrolein exposure in mice
was an expected outcome in this study, as it has been previously demonstrated
clinically [104, 113]. However, the ability of acrolein to accumulate locally in the
CNS following acute acrolein inhalation was of particular interest given the role of
acrolein in cases of neurological disease and trauma [44, 58, 95, 98, 100]. The
increased presence of acrolein-lysine adducts in the spinal cords of mice subjected
to acrolein inhalation suggests that acrolein is not confined to systemic circulation
upon absorption through the lungs, but rather is able to disperse into the CNS and
likely other tissues. Previous data indicating the pathological role of endogenously
produced acrolein in EAE and MS, raises the hypothesis that environmental
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exposure to acrolein could impact clinical course, potentially exacerbating
symptoms or accelerating disease pathogenesis and progression[56].
Known relationships between both acrolein and cigarette smoking, acrolein
and clinical MS and animal models, and clinical observations of adverse effects of
smoking in MS patients suggest that the relationship between acrolein, smoking
and MS warrants further study. This is further supported by data from this study,
indicating that 3-HPMA is significantly higher in MS patients who self-reported as
cigarette smokers compared to MS patients who did not smoke. Furthermore, MS
smokers demonstrated significantly higher EDSS scores at the time of sample
collection, indicating that higher 3-HPMA levels could potentially correspond with
a more severe clinical course. Given the data indicating that endogenous acrolein
levels are elevated in MS patients and the successful application of acrolein
scavengers in EAE mice, clinical application of acrolein scavengers may serve as
a potential therapeutic approach in MS, especially in MS patients who smoke
cigarettes.
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CHAPTER 7. ACROLEIN ELEVATION IN BOTH RR MS PATIENTS AND RR
EAE AND SYMPTOM ALLEVIATION IN RR EAE BY HYDRALAZINE

7.1

Introduction

RR MS is the most common subtype of MS, representing nearly 85% of
current MS cases [13]. However, to date, research of acrolein in MS animal models
has exclusively been conducted in EAE mice induced with a MOG emulsion, which
mimics the PP and SP disease subtypes. In order to facilitate the translation of
acrolein research to the therapeutic tools in the MS patient population, it is crucial
to investigate the clinically observed acrolein elevations in RR MS patients, by
conducting an investigation similar to that conducted by Leung and colleagues in
2011 in an animal model that mimics RR MS disease course. In the current study,
a PLP emulsion was used to induce RR EAE in mice [56]. Analyses of urine
samples and CNS tissue samples are ongoing, however materials and methods,
preliminary findings and a brief discussion are presented in the following sections.

7.2

Materials and methods

7.2.1 Subject Enrollment
See 5.2.5
7.2.2 Clinical Urine Collection
See 5.2.6
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7.2.3 Clinical Serum Collection
See 5.2.7
7.2.4 RR EAE induction and behavioral assessment
Female SJL mice were injected with 0.5 mL PLP/Complete Freund’s
adjuvant emulsion at a total of four sites; two subcutaneously bilaterally to the
caudal spinal column (shoulders) and two subcutaneously bilaterally to the rostral
ends of the spinal column (hips) (Hooke Laboraties, Lawrence, MA). The emulsion
triggers autoimmune recognition of PLP by T-cells and due to nature of immune
response most closely mimics clinical MS. Behavioral assessment was carried out
in accordance with the scale provided by Hooke, briefly described below. 0—no
deficit; 0.5—limp tip of tail; 1.0—complete tail paralysis; 1.5—limp tail + hindlimb
inhibition; 2.0—limp tail + hindlimb weakness; 2.5—limp tail + hindlimb dragging;
3.0—limp tail + complete hindlimb paralysis; 3.5—3.0 score + hunched
appearance or inability to rollover if placed on its side; 4.0—3.0 score + partial
forelimb paralysis; 4.5—4.0 score + lethargy and minimal responsiveness to
sensory stimulation; 5.0—mouse rolling around cage or death/euthanization.
7.2.5 Hydralazine Preparation and Application
Hydralazine hydrochloride was prepared for a final delivery concentration
of 1 mg/kg following dissolution in phosphate buffered saline. The solution was
then filtered for sterilization. Beginning from the day of model induction, mice
received daily intraperitoneal injections of hydralazine until study conclusion 45
days post-induction.
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7.2.6 Animal Urine Collection
See 5.2.4
7.2.7 3-HPMA Anaylsis In Progress
See 5.2.8
7.2.8 Dot Immunoblotting In progress
See 5.2.3
7.3

Preliminary Results

7.3.1 Clinical 3-HPMA Elevations in Urine and Serum of RR MS Patients
A metabolite specific for acrolein following reaction with GSH, 3-HPMA, was
detected at higher concentrations in the urine and serum of RR MS patients (urine:
1.123±0.255 μg/mg creatinine; serum: is 0.069±0.013 μg/g protein; n=31) relative
to healthy controls (urine 0.570±0.082 μg/mg creatinine; serum: and 0.036±0.004
μg/g protein; p<0.05 and p<0.01, respectively; n=23) (Figure 7.1). Notably, while
many data points of MS patients were distributed in the same range as that of
control, there were still multiple points of MS that were greater than that of control,
some by multiple folds.
7.3.2 Daily Hydralazine Application Ameliorated Motor Deficit in RR EAE Mice
Though 3-HPMA quantification and acrolein-lysine adduct assessment in
spinal cords is not yet completed for this study, preliminary behavioral data
suggests that acrolein is indeed elevated in RR EAE due to alleviation of motor
deficit following hydralazine treatment. Furthermore, hydralzine seems to have
effectively shortened relaspse latency, delayed onset of symptoms and decreased
severity during relapse, although statistical analyses of the data are also ongoing.
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Furthermore, a number of MS patients who participated in the study, were found
to have systemic 3-HPMA concentrations within the range of what is considered
“normal”. The reason for the observed discrepancy could lie in the relapsingremitting nature of the pathology. In other words, MS patients that exhibited
nonpathological concentrations of acrolein could be in remission and not
experiencing any symptoms. Longitudinal studies are warranted to pursue this line
of investigation, to monitor acrolein dynamics in multiple phases of the disease,
especially acrolein levels immediately preceding and during a relapse. In the event
that an MS attack is able to be predicted by a rise in systemic acrolien
concentration, this finding would revolutionize current therapeutic approaches to
the diagnosis, symptom management and treatment regimens in the 2.5 million
MS patients.
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Figure 7.1 Quantification of 3-HPMA in the Urine and Serum of RR MS patients.
(A). Bar graph demonstrate the average value of urine 3-HPMA. Specifically, the
average concentration of urine 3-HPMA is 1.123±0.255 μg/mg creatinine for
RRMS patients (N = 31) and 0.570±0.082 μg/mg creatinine for healthy
individuals (N = 23). (: P < 0.05 when RRMS were compared to control, t-test).
(B) Bar graph demonstrate the average value of serum 3-HPMA. Specifically, the
average concentration of serum 3-HPMA is 0.069±0.013 μg/g protein for MS
patients (N = 41) and 0.036±0.004 μg/g protein for healthy individuals (N = 23).
(: P < 0.01 when RRMS were compared to control, t-test). Data in A and B is
expressed as average±SEM. (C) and (D). Scatter plot of the same data used in
(A) and (B), including all the data points to reveal the range and distribution of
measured values. Solid lines indicate the average level of 3-HPMA in both MS
patients and control individuals in urine (C) and in serum (D).
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Figure 7.2 Hydralazine Application in RR EAE Alleviates Motor Deficit.

7.4

Discussion of Preliminary Findings

In order to determine the clinical applicability of acrolein research it is
important to investigate its pathological role in each subtype of MS. To our
knowledge, the current study is the first to focus on detecting and
pharmacologically targeting acrolein in an RR EAE model, induced using a
PLP/Complete Freund’s adjuvant emulsion. Although, analyses of data obtained
from this study is ongoing, clinical acrolein assessment in RR MS patients and
observed behavioral trends in RR EAE with and without the application of acrolein
scavenger hydralazine. Our findings strongly suggest that acrolein underlies
symptomatic development in RR EAE, indicated by therapeutic benefit of acrolein
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removal and in RR MS indicated by the concordant increase of acrolein in MS
patient urine and serum samples compared to healthy controls.
In light of this evidence, we hypothesize that the 3-HPMA and dot
immunoblotting analyses scheduled to be performed in this study, will indicate both
a local and systemic rise in acrolein and that anti-acrolein therapy is
neuroprotective, preserving CNS structure and alleviating pathological acrolein
concentrations contributing to symptomatic development in MS patients.
.
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CHAPTER 8. FURTURE DIRECTIONS

8.1

Examine the Effects of Exogenous Acrolein Exposure on Development of
the EAE Model
Current data indicates that acrolein is potentially an underlying pathological

factor linking MS and tobacco smoking and could explain the observation in
epidemiological studies and in clinical data presented above indicating that
cigarette consumption exacerbates MS symptoms and may accelerate disease
progression. In order to further explore the relationship between acrolein, MS and
cigarette smoking, a comprehensive study must be carried out in an EAE model,
in which animals are subjected to respiratory acrolein exposure in controlled
experimental setting. We propose a study consisting of three experimental groups:
EAE mice exposed to respiratory acrolein with sham saline treatment, EAE mice
exposed to respiratory acrolein with hydralazine treatment and EAE mice with
sham acrolein inhalation exposure and sham saline treatment. If exposure to
respiratory acrolein is capable of exacerbating symptoms and/or accelerating
disease onset/progression in the EAE model, this would indicate acrolein is at least
partially responsible for symptoms in EAE. Alleviation of these affects and
attenuation of motor deficits following the application of an acrolein scavenger in
EAE mice subjected to acrolein inhalation would provide further evidence of the
validity and the translational nature of this relationship. Furthermore, if the results
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from the animal model are consistent with observations in clinical MS cases,
avoidance of exogenous acrolein exposure in cigarettes, fried food, pollution and
occupational settings could prove to be a useful preventative care strategy to
establish public health guidelines for people at risk for developing MS..

8.2

Employment of Minimally Invasive Neuroimaging Techniques with 3-

HPMA Quatification to Determine How Endogenous Acrolein Concentration
Corresponds with CNS Structural Damage
In order to establish acrolein as a biomarker in EAE and MS, a study that
quantifies both degree of CNS structural disruption and endogenous acrolein
concentration is warranted. Such a study would reveal if there is a positive
relationship between acrolein levels and disease activity and if, more importantly,
if increases in acrolein values could potentially be used to predict relapses in
both the RR EAE model or clinical MS cases. The clinical applicability and
noninvasive nature of the 3-HPMA detection in combination with MRI (structural
and Gd-contrast) imaging, ensures the feasibility of this line of questioning in
both a controlled EAE model and MS patients. Knowledge gained from this line
of questioning has the potential to revolutionize clinical approaches for diagnosis,
guiding therapeutic regimens and monitoring disease activity in MS patients..
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